



German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions

Elke Kalbe¹ · Ann-Kristin Folkerts¹ · Karsten Witt^{2,3,4} · Carsten Buhmann⁵ · Inga Liepelt-Scarfone^{6,7,8} · for the German Parkinson's Guidelines Group

Received: 10 April 2024 / Revised: 3 June 2024 / Accepted: 7 June 2024 / Published online: 9 August 2024
© The Author(s) 2024

Abstract

Background and objective Cognitive impairment and dementia as well as affective disorders are common and debilitating syndromes that develop in people with Parkinson's disease (PwPD). The authors summarized recommendations for the 2023 updated German guidelines on “Parkinson's disease” from the German Neurological Society (DGN), focusing on the diagnosis and treatment of these disorders.

Methods The recommendations were based on literature reviews, other relevant guidelines, and expert opinions.

Results Measurements to assess cognitive and affective states were reviewed for psychometric properties, use in routine clinical practice, and availability in German. To improve mild cognitive impairment, cognitive training and physical aerobic training are recommended. To treat Parkinson's disease (PD)-related dementia, cognitive stimulation (as a non-pharmacological intervention) and acetylcholinesterase inhibitors (AChEIs, i.e., rivastigmine) are recommended. Cognitive behavioral therapy is recommended to treat depression, anxiety, and fear of progression. Physical interventions are recommended to treat depression, fatigue, and apathy. Optimized dopaminergic treatment is the first-line pharmacological strategy recommended to manage depression, apathy, anhedonia, fatigue, and mood swings. Major depression can be additionally treated using venlafaxine or desipramine, while moderate depression can be treated pharmacologically according to its clinical phenotype (psychomotor retardation or agitation) and comorbidities (e.g., sleep disturbances, pain). Venlafaxine and nortriptyline can be used to treat anhedonia, while citalopram can be used for anxiety.

Conclusions In addition to the updated pharmacological treatment options, new insights into recommendations for standardized diagnostics and non-pharmacological interventions were provided for the German health care system. However, more studies are needed to explore the full potential of non-pharmacological interventions to treat and prevent cognitive impairment and affective disorders.

Keywords Mild cognitive impairment · Dementia · Depression · Anxiety · Parkinson's disease · Guideline

Introduction

In people with Parkinson's disease (PwPD), cognitive impairment, including Parkinson's disease mild cognitive impairment (PD-MCI) and Parkinson's disease dementia (PDD), as well as affective disorders, are the most common and debilitating non-motor symptoms [1–3]. However, affective disorders are still largely underdiagnosed [4]. For the

best medical treatment, the standardization of diagnostic and therapeutic strategies is of the utmost importance.

The new German S2k guidelines for “Parkinson's disease” (PD) provide up-to-date recommendations for the diagnosis and treatment of PwPD in clinical practice [5]. This paper summarized the guidelines' chapters of “[Cognitive impairment](#)” and “[Affective disorders](#).” In the “[Cognitive impairment](#)” chapter, both diagnostic and treatment guidelines for PD-MCI and PDD are included, and in the “[Affective disorders](#)” chapter, guidelines for the diagnosis

Extended author information available on the last page of the article

and treatment of depression, anhedonia, apathy, anxiety, and fear of progression are included. Fatigue is also considered.

What is new in the novel S2k guidelines?

Contrary to its previous version, the new S2k guidelines refer to criteria and assessments that can be used to support the diagnosis of cognitive impairment and affective disorders in PwPD in clinical practice. In its recommendations for treatment, both non-pharmacological and pharmacological interventions are considered. The main recommendations are:

Cognitive disorders

- Proposal of diagnostic criteria and cognitive assessments for PD–MCI and PDD, as well as measures to assess activities of daily living (ADL) to further support the diagnosis of PDD
- Treatment of PD–MCI with cognitive training and physical interventions
- Therapy for PDD with cognitive stimulation, the acetylcholinesterase inhibitor (AChEI) rivastigmine, and the off-label use of donepezil

Affective disorders

- proposal of medical history questions and scales to assess affective disorders
- treatment of depression, anxiety, and fear of progression with cognitive behavioral therapy (CBT); treatment of depression, apathy, and fatigue with physical interventions
- optimization of dopaminergic medication as a first-line strategy to manage depression, apathy, anhedonia, mood swings, and fatigue
- treatment of depression, anhedonia, apathy, anxiety or panic, and fatigue with non-dopaminergic medication following the results of randomized controlled trials (RCTs), individual antidepressant effect profiles, clinical phenotypes, and comorbidities; treatment with venlafaxine or desipramine for major depression; treatment with venlafaxine, citalopram, or sertraline for moderate depression and coexisting psychomotor retardation; treatment with mirtazapine or trazodone for moderate depression and coexisting agitation; treatment with amitriptyline for moderate depression and comorbid sleep disturbances, hypersalivation, or pain in cognitively intact PwPD; treatment with venlafaxine or nortriptyline for apathy, citalopram for anxiety, and modafinil or safinamide for fatigue.

Methodology

The new guidelines were prepared as S2k guidelines and recommendations were based on a structured consensus process. The author team of the chapters dealing with cognitive and affective disorders in PwPD comprised an interdisciplinary group of experts from the fields of neurology (KW, CB), neuropsychology (EK, ILS), and gerontology (AKF). This team developed the key questions that were chosen for the preparation of the recommendations, and the editorial board of the PD guidelines consisting of the publishing association, i.e., the German Neurological Society (DGN), further professional associations and organizations, and experts from the field approved them.

The recommendations were based on (1) literature reviews conducted in the MEDLINE database considering meta-analyses, RCTs, and other relevant studies; (2) German national guidelines that are also relevant for PwPD, i.e., guidelines for the diagnosis and treatment of dementia [6], unipolar depression [7], and anxiety disorders [8]; (3) recommendations from the International Parkinson and Movement Disorder Society (MDS); (4) expert opinions based on clinical expertise and knowledge of the literature; (4) previous versions of the PD guidelines for all questions that were represented therein.

The recommendations followed a “should/should not,” “can/cannot,” or “might/might not” sentence structure. The editorial board of the PD guidelines then discussed and approved the recommendations. Based on the discussions, some revisions were necessary. The final recommendations were then voted on and classified according to their consent of approval rates (strong consent: >95% positive votes; consent: >85–95% positive votes; majority agreement: >50–85% positive votes; no majority agreement: <50% positive votes).

Cognitive impairment

Definition, epidemiology, and clinical presentation

Cognitive impairment is one of the most common non-motor symptoms in PwPD [9]. Between 60% and 83% of PwPD progress to PDD during the disease course, especially in more advanced stages [10]. To prevent or delay PDD is urgent, as PDD lowers PwPDs’ health-related quality of life, increases the risk for nursing home placement and mortality, and increases caregiver burden [11]. PD–MCI is considered a possible transitory stage from normal cognition to PDD. Even though not all people with PD–MCI will develop PDD, the presence of PD–MCI,

prevalent in 25–30% of PwPD. Therefore, PD-MCI is one of the greatest risk factors for the development of PDD [9, 12], on average, one-third of people with PD-MCI develop dementia within 7 years [13]. Initial evidence has confirmed that the non-pharmacological treatment of people with PD-MCI can enhance or stabilize cognitive function [9]. Older age, male gender, postural instability and gait symptoms, a genetic vulnerability, and concomitant amyloid and tau pathology have also been demonstrated to contribute to the worsening of cognitive function in PwPD [14].

Cognitive impairment in PwPD affects various functions, including executive function, attention, working memory, memory, visuocognition and language [15]. Besides worsened cognition, loss of the abilities to perform ADL is the core criterion for the diagnosis of PDD [16, 17]. Most importantly, ADL impairment indicative of dementia is primarily caused by cognitive impairment, not by motor or other non-motor dysfunction. The occurrence of behavioral abnormalities (e.g., hallucinations, apathy) further supports the diagnosis of PDD [18].

Assessment of cognitive impairment

Besides the diagnosis of PD according to consensus guidelines [19, 20], a slow progressive decline in cognitive function, reported either by the PwPD themselves, a third party, or an investigator, within the frame of a long-standing disease course characterizes cognitive impairment in PD [15, 16, 18].

The MDS Task Force [15, 16] recommends two levels of assessment to diagnose PD-MCI and PDD: (1) a short screening for impairment assessed with global cognitive scales and/or impairment in specific cognitive tasks (Level I) and (2) a detailed neuropsychological assessment using at least two tests to evaluate deficits in each of the following domains: executive function, attention, working memory, memory, visuocognition, and language (Level II). Diagnoses of cognitive impairment should be based on assessments with sufficient psychometric properties [15]. Therefore, as a highly novel aspect of these guidelines, it is recommended to use scales available in German to assess global cognition and ADL measures in order to support the diagnosis of cognitive impairment in PD. “*Should be used*” recommendations are to be used if there is sufficient accuracy for diagnosis of cognitive impairment (PD-MCI or PDD) evaluated in international (non-German speaking) and national (German speaking) cohorts, acceptable diagnostic properties (reliability, validity, and sensitivity of change), and if all relevant aspects of impairment are detected by the measurement. “*Can be used*” recommendations are to be used if there is sufficient accuracy for diagnosis of cognitive impairment (PD-MCI or PDD) evaluated in international (non-German

speaking) or national (German speaking) cohorts or if cognitive deficits are detected in national cohorts, but incomplete information about diagnostic properties is reported (including reliability, validity, and sensitivity of change) or if not all relevant aspects of (cognitive or ADL) impairment are detected by the measurement. “*Might be used*” recommendations are to be used if sufficient diagnostic accuracy in the assessment of a cognitive impairment diagnosis (PD-MCI or PDD) is evaluated in international (non-German speaking) or national (German speaking) cohorts and if acceptable diagnostic properties in other diseases are given but no information about diagnostic properties in PwPD is available in the German version.

An overview of the diagnostic properties of recommended assessments is displayed in Supplementary Table 1. Scale properties and the diagnostic accuracy of the Montreal Cognitive Assessment (MoCA) for PD-MCI and PDD have been confirmed in international and national cohorts [21–25], and age-, gender-, and education-corrected standard scores are available [26].

The diagnostic properties of the German Mattis Dementia Rating Scale (MDRS) have been validated in international studies, but these properties have not yet been defined in the German version [27]. There is evidence that in the German version of the MDRS, the cognitive performance of PwPD and healthy controls differs greatly (Cohen’s d : $0.99 \leq d \leq 1.01$) [28], confirming that the MDRS can detect cognitive impairment in PwPD.

The Parkinson Neuropsychometric Dementia Assessment (PANDA) has been shown to have sufficient reliability and validity for PDD [29], but its diagnostic value has not yet been confirmed for PD-MCI [28]. Additionally, no specific subscale to assess attention is included in the PANDA, and sensitivity of change has not yet been defined in national PD samples [21]. However, since the PANDA includes highly sensitive measures to assess mild cognitive dysfunction in PwPD, it is suggested for use, on the basis of an expert rating, for the Level I diagnosis of PD-MCI.

Scales for Outcomes in Parkinson’s Disease–Cognition (SCOPA–COG) and various versions of the Addenbrooke’s Cognitive Examination (ACE) lack either the confirmation of acceptable scale properties (reliability and sensitivity of change) or the validation of diagnostic accuracy in German cohorts. Further critique of the SCOPA–COG concerns its high weight for memory function on the global scale [21].

Due to its low sensitivity, the Mini Mental State Examination (MMSE) is only recommended for the Level I diagnosis of PDD. The MDS Task Force recommends a cut-off of <26 points for the MMSE [21], but higher (<29 points, sensitivity of 78%, specificity of 63%, [30]) and lower (<25 points, sensitivity of 71%, specificity of 90%, [24]) cut-off scores have also been reported [24, 30]. As a further limitation, the MMSE does not include items to assess executive

function [21]. For the German version, age-, gender-, and education-corrected norm values are available and recommended [31].

Recommendations for scales to assess cognitive impairment (new)

Cognitive screening tools should be used for the Level I diagnosis of PD–MCI. Corrections for age, education, and, if necessary, gender should be applied whenever available

The following instruments are particularly suitable (*can be used*)

- MoCA with a cut-off of <26 points
- MDRS with a cut-off of <140 points

The following instruments are also recommended (*might be used*)

- SCOPA–COG with a cut-off of <30 points
- ACE or ACE–R with cut-off values dependent on education
- PANDA with a cut-off of <17 points

Level of consensus: 100%, strong consensus

Cognitive screening tools should be used for the Level I diagnosis of PDD. Corrections for age, education, and, if necessary, gender should be applied whenever available

The following instruments are particularly suitable (*can be used*)

- MoCA with a cut-off of <21 points
- MDRS with a cut-off of <123 points
- MMSE with a cut-off of <26 points
- PANDA with a cut-off of <15 points

The following instruments are also recommended (*might be used*)

- SCOPA–COG with a cut-off of <23 points
- ACE or ACE–R with cut-off values dependent on education

Level of consensus: 100%, strong consensus

For the Level II diagnosis of PD–MCI, the following aspects must be considered:

- For Level II testing, two tests should be used for each of the five cognitive domains (executive function, attention and working memory, memory, language, visuocognition)
- At least two tests of different functions in a cognitive domain should be used to diagnose domain-specific cognitive disorders
- A value in the range of 1–2 standard deviations below the population mean should be used as a cut-off to define cognitive impairment

Level of consensus: 100%, strong consensus

The following aspects must be considered for the Level II diagnosis of PDD:

- To confirm the diagnosis of PDD using Level II testing, two tests should be used for each of the five cognitive domains (executive function, attention and working memory, memory, language, visuocognition)
- A value in the range of 1–2 standard deviations below the population mean should be used as a cut-off to define cognitive impairment

Level of consensus: 96.6%, strong consensus

ACE Addenbrooke's cognitive examination; *ACE–R* Addenbrooke's cognitive examination–revised version; *MoCA* Montreal cognitive assessment; *MDRS* Mattis dementia rating scale; *MMSE* Mini mental state examination; *PANDA* Parkinson neuropsychometric dementia assessment; *SCOPA–COG* Scales for outcomes in parkinson's disease–cognition; *PDD* Parkinson's disease dementia; *PD–MCI* Parkinson's disease mild cognitive impairment

In contrast to the abbreviated Level I procedure, a comprehensive Level II neuropsychological assessment has shown better diagnostic accuracy for cognitive impairment in PwPD [25, 32]. The application of two tests per cognitive domain has indicated highest diagnostic accuracy for PD–MCI [33]. Normed neuropsychological tests across multiple cognitive domains have also consistently detected PD-related cognitive deficits compared to controls [34]. Recommendations for Level II diagnostic criteria for PD–MCI and PDD thus follow international consensus guidelines [16, 17].

Recommendations for the assessment of activities of daily living daily living activity impairment to support a diagnosis of Parkinson's disease dementia

Significant ADL impairment associated with worsening cognition is a core criterion for PDD [16]. A differentiation can be made between basic ADL (BADL), which are necessary for self-maintenance (e.g., dressing, eating), and more complex instrumental ADL (IADL, e.g., managing finances) [35, 36]. Evaluating the potential of patient-, informant-, and investigator-rated ADL measures is still new. Diagnostic values have often not been confirmed in independent PD cohorts, but the assessments can differentiate between groups of PwPD with and without cognitive impairment (either PD–MCI or PDD) [37–41]. Therefore, applying scales has been limited to orienting screening procedures for further extensive interviews. To date, the Lawton and Brody informant Rating IADL Scale (cut-off < 19 points: sensitivity of 71%; specificity of 82%) [42], investigator-rated Unified Parkinson's Disease Rating Scale II (UPDRS-II) (cut-off > 15 points: sensitivity of 67%; specificity of 78%) [42], Schwab and England Scale (cut-off < 75%: sensitivity of 71%; specificity of 77%) [42], Parkinson's Disease Cognitive Functional Rating Scale (PD–CRFS, cut-off < 6 points: sensitivity of 83%; specificity of 83%) [43], and performance-based Pill Questionnaire (sensitivity of 89–91%, specificity of 89–91%) [42, 44] have been recommended as ADL screening tools for PwPD. The following German ADL assessments might also be considered as screening tools for ADL impairment to support a PDD diagnosis but have not been evaluated in international cohorts [43]:

- Nürnberger Alters Inventar Beobachtungsskala (NAB)–ADL (NAB–ADL, cut-off > 22 points: sensitivity of 81%; specificity of 80%)
- Nürnberger Alters Inventar Aktivitäten Skala (NAA)–ADL (NAA–ADL, cut-off > 34 points: sensitivity of 76%; specificity of 85%)

- Nurses' Observation Scale for Geriatric Patients (NOSGER)–ADL (cut-off > 7 points: sensitivity of 67%; specificity of 86%)
- NOSGER–IADL (cut-off > 11 points: sensitivity of 62%; specificity of 67%)

Recommendations for instruments to assess activities of daily living impairment to support a diagnosis of Parkinson's disease dementia (new)

- For the exploration of ADL impairment, the following can be used: the informant-rated IADL questionnaire by Lawton and Brody, with a cut-off of <19 points; the UPDRS-II, with a cut-off of >15 points; the PD-CRFS with a cut-off of >6 points, the Schwab and England Scale, with a cut-off of <75%; the Pill Questionnaire
- The following scales might be used to assess ADL impairment: the NAB–ADL, with a cut-off of >22 points; the NAA–ADL with a cut-off of >34 points; the NOSGER–ADL, with a cut-off of >7 points; the NOSGER–IADL, with a cut-off of >11 points

If the test result is positive, further measures (e.g., medical history) should be utilized to verify whether ADL impairment is primarily caused by cognitive deterioration (expert opinion)

Level of consensus: 100%, strong consensus

ADL Activities of daily living; IADL Instrumental activities of daily living; NAA-ADL Nürnberger-Alters-Inventar Aktivitäten-Skala; NAB-ADL Nürnberger-Alters-Inventar Beobachtungsskala; NOSGER-ADL Nurses' observation Scale for geriatric patients activities of daily living scale; NOSGER-IADL Nurses' observation scale for geriatric patients instrumental activities of daily living scale; PD-CRFS Parkinson's disease cognitive functional rating scale; PDD Parkinson's disease dementia

The non-pharmacological treatment of cognitive impairment in people with Parkinson's disease

Cognitive interventions: general remarks

Non-pharmacological interventions, and especially cognitive interventions, have been considered promising therapeutic approaches to treat cognitive impairment in PwPD. Different forms of cognitive interventions can be distinguished: cognitive training, cognitive rehabilitation, and cognitive stimulation [45]. Cognitive training and rehabilitation appear to be particularly suitable for PD–MCI due to their level of difficulty and objectives. Cognitive stimulation, on the other hand, is more likely to be indicated for more advanced cognitive impairment or dementia. Cognitive training involves the use of standardized analog or digital tasks (e.g., with a laptop, tablet, or smartphone) that are directly aimed at training specific cognitive functions (e.g., executive function, attention, memory). It is often possible to adapt the difficulty level of the exercises to the individual's cognitive level.

Cognitive rehabilitation represents an individualized approach that is offered in practice as individual therapy. Individual everyday goals for cognitive rehabilitation are defined in collaboration with the patient and their relatives. Psychoeducation is often part of cognitive rehabilitation. Cognitive stimulation is usually conducted in a small group setting with a wide range of enjoyable activities to indirectly stimulate cognitive and social skills.

Cognitive training to treat Parkinson's disease mild cognitive impairment

Studies evaluating treatment effects on PD–MCI in mixed cohorts of “non-demented” (with and without PD–MCI) or “cognitively impaired” (PD–MCI and PDD) PwPD were excluded from treatment recommendations, unless effects were separately reported for PD–MCI.

Among the seven RCTs comparing “classical” digital cognitive training with passive or active control groups, four showed that the experimental group was superior, indicating benefits to various cognitive outcomes like global cognition, executive function, attention, memory, visuocognition, and processing speed [46–49]. In two further studies, different cognitive and psychoeducational training (digital and non-digital) were compared, and they demonstrated positive effects on cognition in all training groups [50, 51]. Two RCTs evaluated the effects of digital training with gamification approaches, one of which used virtual reality training [52] and the other of which used cognitive training set up as a computer game [53]; both studies showed superiority in cognitive outcomes compared with analog cognitive training [52] and a passive control group [53]. Four RCTs that used analog cognitive training indicated superiority compared to active control groups in various cognitive outcomes [54–57].

However, the above-mentioned studies should be analyzed with caution, as most of them (1) had small sample sizes; (2) had different diagnostic criteria and used different test batteries (e.g., with or without using the MDS criteria for PD–MCI and PDD [15]); (3) lacked consideration of disease severity in the analysis of training effects; (4) had different outcomes, some of which were not clearly defined; (5) had heterogeneous training types (i.e., digital vs. analog training, individual vs. group training) that differed in duration and intensity. Therefore, recommendations for specific training characteristics were difficult to distinguish. Besides these limitations, current evidence has indicated the cognitive benefits of cognitive training in individuals with PD–MCI. This is consistent with the results of systematic reviews and meta-analyses evaluating the treatment effects of cognitive interventions in PwPD [58–60], which also include studies with PwPD without cognitive impairment or mixed cohorts (with and without PD–MCI). Cognitive training can

thus be recommended for cognitive impairment. Furthermore, data have indicated that digital cognitive training can be particularly effective for cognitive impairment [52, 53]. However, analog training and training in both group and individual therapy settings have also shown positive effects [46–49]. Even if home-based training (especially digital) is available, the therapy should, if possible, be supervised in outpatient as well as inpatient settings. Training should also consider patients' interests and circumstances (e.g., digital vs. analog training, group vs. individual training) to achieve a high level of therapy adherence. Multi-domain training (in which several cognitive domains are addressed, e.g., executive function, attention, and memory) appears to be appropriate since several cognitive domains are affected in most PD–MCI cases. However, training studies considering individual domains, especially executive function, have also shown positive effects and can therefore also be recommended. No statements can be made about transfer effects on non-trained cognitive and non-cognitive domains due to a lack of evidence, though. Regarding duration and frequency of the cognitive training, no clear recommendations can be drawn from the evidence. However, based on expert discussions, the authors recommend persistent cognitive training including several training sessions per week.

Recommendations for cognitive training to treat Parkinson's disease mild cognitive impairment (new)

Cognitive training can be offered

Level of consensus: 96.6%, strong consensus

Cognitive interventions to treat Parkinson's disease dementia

To evaluate the effects of cognitive interventions to treat PDD, only studies in which individuals with PDD were analyzed as a separate study group were considered. Accordingly, the available studies that investigated and reported on mixed populations (e.g., individuals with PDD and Dementia with Lewy Bodies) were excluded.

Cognitive stimulation is recommended in the S3 guidelines for the diagnosis and treatment of dementia [6] (*should be offered*). However, no distinction is made between dementia types with different etiologies, so the specific effect on people with PDD is unclear. In the 2023 published Cochrane review on the evaluation of cognitive stimulation in (all-cause) dementia [61], 37 RCTs with a total of 2766 people with dementia were included. The authors concluded that cognitive stimulation shows small, short-term, positive effects on global cognition, communication, social interaction, quality of life, and psychological and behavioral symptoms in cases of mild to moderate dementia. However, again, dementia types were not differentiated. For people

with PDD, one crossover pilot RCT investigated the effects of a cognitive stimulation program [62]. Despite the very small sample size ($N=12$ in the experimental group, $N=6$ in the control group receiving treatment as usual), there was a statistical trend indicating the superiority of the experimental group over the control group in global cognition, mood, and behavioral symptoms.

The German S3 guidelines for the diagnosis and treatment of dementia [6] also recommend reminiscence therapy for dementia with different etiologies. The Cochrane review published in 2018 [63] with a total of 22 RCTs involving 1972 people with dementia with different etiologies showed the positive effects of reminiscence therapy on cognition, quality of life, communication behavior, and mood. However, no specific evidence exists for people with PDD. Overall, a *might be used* recommendation was derived.

A Cochrane review on cognitive training in mild to moderate dementia with different etiologies published in 2019 [45] presented data indicating mild to moderate positive effects on global cognition and verbal fluency, but to date, no studies on PDD have been conducted. Furthermore, cognitive training and cognitive rehabilitation are not recommended in the S3 guidelines for people with dementia [6]. Therefore, no recommendations for cognitive training and cognitive rehabilitation for PDD were derived.

Recommendations for cognitive interventions to treat Parkinson's disease dementia (new)

Cognitive stimulation can be offered

Reminiscence therapy might be offered

Level of consensus: 96.8%, strong consensus

Physical training: general remarks

Endurance training and other forms of physical activity reduce the risk of cognitive impairment [64] and dementia in healthy older people [65]. Moreover, people with Alzheimer's disease benefit from endurance exercise delivered in a dose-dependent manner, as it improves executive performance in particular [66]. Increasing evidence has demonstrated that physical training interventions may also improve cognition in PwPD [67]. Notably, a higher "lifetime physical training load" has been associated with better global cognition in PwPD [68].

Physical training to treat Parkinson's disease mild cognitive impairment

Only physical training studies that defined cognition as a primary outcome were considered. Studies examining the effects of exergaming were excluded, as exergaming combines physical and cognitive training, so the specific

effects of physical training could not be determined. In total, 23 studies were identified as relevant to the guidelines, only one of which focused exclusively on people with PD–MCI and not on mixed samples of PwPD with no cognitive impairment and PD–MCI.

The only RCT that used PD–MCI as an inclusion criterion ($N=50$) showed the superiority of endurance training (6 times per week for 60 min over 4 weeks) for global cognition, attention, and working memory after 4 weeks compared to a passive control group. This superiority of the training group in global cognition was still present after 6 months [69].

Regarding trials with mixed samples of PwPD with and without cognitive impairment, one RCT ($N=76$) indicated that endurance training is superior over an active control group (i.e., walking, stretching) in terms of its improvement of executive function over time, with both training types conducted 3 times per week for 60 min over 12 weeks [70]. Another small study ($N=9$) with PwPD without cognitive impairment showed the superiority of treadmill training (3 times per week for 45 min over 3 weeks) in frontal functions compared to a passive control group [71]. In a non-randomized study with 11 PwPD participating in endurance training (3 times per week for 60 min over 6 months), the training group was again superior to a passive control group in executive function [72]. A systematic review of RCTs also showed an advantage of physical activity over passive control groups in the areas of global cognition, cognitive flexibility, attention, and cognitive processing speed [73].

For a detailed description of the recommendation, one systematic review [73], two RCTs [69, 70], and a non-randomized study evaluating physical exercise training [71] were used, the latter because the study defined cognitive variables as its primary outcome. As the above mentioned studies varied in time per session (45–60 min), frequency of session per week (3–6 times) and the total number of training weeks (3–24 weeks), the recommendation for the duration and frequency of physical exercise training was based on an expert consensus considering the current state of knowledge [69–73] as well as practical issues to conduct physical training in the clinical care (e.g. PwPD with a long journey might not be able to conduct 3 sessions per week). The optimal training intensity and frequency for PD–MCI have not been investigated yet, but should be the focus of future studies. Additionally, no differentiation regarding the type of endurance training could be made.

Recommendations for physical interventions to treat Parkinson's disease mild cognitive impairment (new)

Physical (aerobic) training should be conducted 2–3 times per week for 45–60 min to treat PD–MCI

Level of consensus: 96.8%, strong consensus

Physical training to treat Parkinson's disease dementia

Only three studies with very small sample sizes comprising people with PDD diagnosed according to established criteria ($n < 5$) were identified [74–76]. Given the lack of sufficient data, the expert team decided that no recommendation could be derived for physical training to treat PDD.

Recommendations for physical interventions to treat Parkinson's disease dementia (new)

Data are insufficient to recommend physical training to treat cognitive symptoms in PDD

Level of consensus: 96.7%, strong consensus

Food supplements and diet to treat Parkinson's disease mild cognitive impairment and Parkinson's disease dementia

Evidence for food supplements, herbal therapeutics, and specific diet approaches as treatment options for PD–MCI and PDD is currently mainly limited to narrative review articles and expert opinions, and no double-blinded placebo-controlled RCT has been published. Ketogenic [77] and Mediterranean diets [78], creatinine, and coenzyme Q10 [79] have demonstrated small improvements in cognitive function in people with PD–MCI, whereas the results of caffeine have been mixed [80, 81]. One study evaluating the effects of a combination of donepezil, DL-3n-butylphthalide oxiracetam, and Ginkgo biloba in people with PDD showed slight improvements in their global cognitive state [82]. However, data were regarded as insufficient to derive any recommendation therefrom.

Recommendations for food supplements and herbal therapeutics to treat Parkinson's disease mild cognitive impairment or Parkinson's disease dementia (new)

Food supplements and herbal therapeutics should not be used to treat cognitive deficits in PD–MCI

Level of consensus: 96.6%, strong consensus

Food supplements and herbal therapeutics should not be used to treat cognitive deficits in PDD

Level of consensus: 96.6%, strong consensus

The pharmacological treatment of cognitive impairment in people with Parkinson's disease

General remarks

Reduced cholinergic activity has been demonstrated in people with PDD [83, 84], but altered cholinergic innervation is already present in the early stage of PD [85–87]. Deficits in

executive function, attention, and memory have been correlated with cholinergic activity assessed via cholinergic [18F] fluoroethoxybenzovesamicol positron emission tomography in PwPD [85]. Memantine is a moderate affinity uncompetitive antagonist of glutamate *N*-methyl-D-aspartate receptors and is effective for treating cognitive dysfunction in people with Alzheimer's disease [88]. Therefore, the efficacy of AChEIs and memantine for cognition has not only been evaluated in PDD but also in PD–MCI.

Pharmacological interventions to treat Parkinson's disease mild cognitive impairment

Studies evaluating the effect of AChEIs on PD–MCI are limited. A trend in favor of rivastigmine treatment (maximum dose of 9.5 mg per 24 h) in the clinical global impression of change as a primary outcome in a 24-week, randomized, double-blinded, placebo-controlled trial [89] but not in cognitive scales, behavior, quality of life, and ADL was shown. Open-label treatment with donepezil (5–10 mg) for 48 weeks in 80 people with PD–MCI showed no change in their global cognitive state [90]. However, treatment with donepezil had a modulatory effect on the electroencephalography of people with PD–MCI. In a mixed group of 145 people with no cognitive impairment and PD–MCI, the efficacy of donepezil (5 mg per day) to improve verbal memory as a secondary outcome but not their global cognitive state was reported in a double-blinded RCT [91, 92]. No study on treatment with galantamine in people with PD–MCI could be identified.

Only one RCT with a crossover design (6-week treatment period) analyzed the effect of memantine (20 mg per day) on 10 people with PD–MCI [93]. It was found that psychomotor speed and working memory worsen under treatment with memantine, but other neuropsychological tests showed no treatment-induced change.

Recommendations for acetylcholinesterase inhibitors to treat Parkinson's disease mild cognitive impairment (new)

Rivastigmine, donepezil, and galantamine should not be used to treat PD–MCI

Level of consensus: 89.7%, consensus

Recommendations for memantine to treat Parkinson's disease mild cognitive impairment (new)

Memantine should not be used to treat PD–MCI

Level of consensus: 96.7%, strong consensus

Pharmacological treatments for Parkinson's disease dementia

Evidence for AChEI treatment has been updated. Data from a meta-analysis confirmed the positive treatment effects of rivastigmine and donepezil on PDD patients' global

cognitive state [94], memory, and speech [95]. However, there is stronger evidence for rivastigmine in meta-analyses. First, meta-analyses did not consistently report positive effects of donepezil on cognitive tests, and positive effects of donepezil on ADL functioning has not been demonstrated yet [96, 97]. In this guideline, we rate positive changes in cognition ("pathophysiological validity") and ADL functions ("ecological validity") higher than a change in the "Clinical Global Impression of Change", as this is dichotomized in meta-analyses ("improvement" versus "stable or worsening") and thus loses some of its statistical significance. Both, changes in cognition (better effectiveness) and positive ADL functions favors rivastigmine [96, 97]. Improvements in neuropsychiatric symptoms have been verified with rivastigmine but not donepezil [94, 95, 98]. Otherwise, it has been shown that treatment with donepezil compared with a placebo leads to improvements in ADL [96]. The occurrence of side effects worsening PD symptoms and tremors has been reported with rivastigmine use but is less prominent with donepezil use [94, 95]. No effect for galantamine treatment has been identified [98].

Two meta-analyses [88, 99] reported only small improvements in cognitive function and global clinical impressions for memantine in people with PDD, but treatment effects were considerably higher in mixed cohorts with PDD and Lewy body dementia.

Recommendations for acetylcholinesterase inhibitors in the treatment of Parkinson's disease dementia (updated)

Rivastigmine should be used

Donepezil might be used (off-label use)

Galantamine cannot be used

Level of consensus: 96.6%, strong consensus

Recommendations for memantine in the treatment of Parkinson's disease dementia (new)

Memantine should not be used

Level of consensus: 96.6%, strong consensus

Table 1 gives an overview of the recommendations for the non-pharmacological and pharmacological treatment of PD–MCI and PDD.

Affective disorders

Definition, epidemiology, and clinical presentation

Affective disorders are highly debilitating and commonly occurring in PwPD. For example, a meta-analysis of 30 studies including $N=7142$ PwPD with a disease duration of more than 3 years found a prevalence of depressive disorders of 47.2%, apathy of 45.5%, and anxiety disorders of 42.9% [1].

Table 1 Overview of recommendations for pharmacological and non-pharmacological treatment of PD-MCI and PDD

	Non-pharmacological treatment			Pharmacological treatment			
	Cognitive intervention	Physical intervention	Nutrition	Memantine	Rivastigmine	Donepezil	Galantamine
PD-MCI	++ Cognitive training	+++ 3×/week aerobic training	–	–	–	–	–
PDD	++: Cognitive stimulation; + reminiscence therapy	–	–	–	+++	+ Off-label use	–

+++ should be offered; ++ can be offered; + might be offered; – no recommendation

However, affective disorders in PwPD are often underdiagnosed and, therefore, untreated, which is likely to have a significant negative impact on their quality of life and overall prognosis [100–104]. For example, in a survey of diagnostic accuracy at the University of Miami, Florida, USA, neurologists overlooked every second case of depression in PwPD with outpatient contact [104]. Further studies have shown that only a quarter of PwPD with depressive disorders receive antidepressant treatment [105, 106].

Depression, anhedonia, and mood swings

According to the draft version of the *International Statistical Classification of Diseases and Related Health Problems* revision 11 (*ICD-11*) [107], depressive disorders are characterized by a depressed mood (e.g., feeling sad, irritable, empty) or joylessness (i.e., anhedonia), accompanied by other cognitive, behavioral, or neurovegetative symptoms that significantly impair the person's ability to function. Studies with PwPD have indicated that there is a close negative correlation between patients' quality of life and the extent of their depressive symptoms, while there is no or a weaker correlation with motor impairments [108, 109]. In a meta-analysis on the prevalence of depressive disorders in PwPD, Cong et al. (2022) [110] found a prevalence of 38% based on 129 studies with $N=38,304$ PwPD. It was also found that depressive disorders are associated with longer disease duration, higher disease severity, and more motor symptoms (especially bradykinesia) and non-motor symptoms (apathy, anxiety disorders, fatigue). Anhedonia, or the inability to feel pleasure, can be a symptom of both depressive and apathetic syndromes [111], and its prevalence has been described to be between 10 and 40% [112]. Studies have indicated that 40–50% of PwPD report motor fluctuations, while much less is known about non-motor fluctuations, which often occur in the domain of emotion and affect. A systematic review indicated that 35% of PwPD experience feelings of anxiety, while 35% also experience symptoms of depression. Panic attacks are also common among PwPD [113].

Apathy

Apathy is defined as a lack of motivation characterized by reduced goal-oriented thinking and action, as well as reduced emotional expression. It is, therefore, a drive disorder that can have a negative impact on the motivation for self-care and is often a major burden for relatives [101]. Meta-analytic data have indicated a prevalence of 40% for apathetic symptoms in PwPD, with the occurrence of apathy being associated with older age, cognitive impairment, the presence of depressive disorders, and more advanced PD symptoms [101].

Anxiety disorders and fear of progression

According to the *ICD-11* [107], anxiety disorders are defined as mental disorders characterized by excessive fear and anxiety and associated behavioral disturbances, with symptoms severe enough to cause significant distress or impairment in personal, familial, social, educational, occupational, or other important areas of functioning. Various diagnoses can be considered anxiety disorder diagnoses, including generalized anxiety disorder, panic disorder, agoraphobia, specific phobias, or social anxiety disorder. In a systematic review with a meta-analysis based on 45 studies with $N=2399$ PwPD, a prevalence of 31% for anxiety disorders in general was identified, with generalized anxiety disorder being the most common type of anxiety disorder at 14% [100]. Furthermore, the point prevalence for social anxiety disorder was 14%, 13% for unspecified anxiety, 13% for specific phobias, and 7% for panic disorder. During the course of chronic diseases, fear of progression has also been described. Fear of progression is a real fear that arises from the experience of a serious, potentially life-threatening, or disabling disease and its diagnosis and treatment [114]. In terms of differential diagnoses, fear of progression must be clearly distinguished from anxiety disorders. In a study that compared chronic diseases in terms of the extent of their associated fear of progression, PD showed the second-highest values [114]. In a cross-sectional study that Folkerts et al. [115] conducted with $N=120$ PwPD, moderate levels of fear of progression

were found in 63% of respondents, while 18% showed dysfunctional levels of fear of progression.

Fatigue

Fatigue in the context of PD is defined as an (almost) daily feeling of “a markedly reduced energy level or increased perception of exertion out of proportion to the activities attempted or the general level of activity” [116]. A distinction can be made between physical fatigue (i.e., the feeling of physical exhaustion or a lack of physical energy) and mental fatigue (i.e., the cognitive effects that occur during and after prolonged periods of sustained mental exertion) [117]. The reported prevalence of fatigue in PwPD has varied widely, ranging from 33 to 70%. It has been found that fatigue is more common in later stages of PD [118]; however, it can also manifest in the premotor stages of PD [119]. Fatigue impairs ADL and significantly limits the social and occupational participation and quality of life of PwPD [120].

The diagnosis of affective disorders in people with Parkinson’s disease

General remarks: challenges in diagnosing affective disorders in people with Parkinson’s disease

The diagnosis of affective disorders in PwPD is challenging, particularly because the signs and symptoms of affective disorders can overlap with motor and other non-motor symptoms. In addition, the diagnostic criteria for depressive disorders that have been established for people without PD, for example, may not be readily applicable to PwPD, as the spectrum of depressive symptoms is not entirely the same [121]. Depressive symptoms in PwPD often include dysphoria, pessimism, anxiety and somatic symptoms, and less frequently, feelings of guilt, failure, self-blame, or suicidality [122–124]. Moreover, feelings of emptiness and hopelessness, reduced responsiveness to emotional stimuli, or loss of the ability to enjoy and feel pleasure (anhedonia) have been described in PwPD [125]. The clinical diagnosis of depression in PwPD usually refers to the presence of such symptoms and not to morning dysphoria, weight loss, or too much or too little sleep [121].

A further challenge for the diagnosis of depressive disorders in PwPD often arises from concomitant dementia. On one hand, possible symptoms of a depressive disorder can also be symptoms of dementia (e.g., anhedonia, irritability [121]); on the other hand, cognitive disorders can also be caused by depression. In advanced PD, an overlap between depression and dementia is common and represents a challenge for differential diagnosis.

Apathy can occur in PwPD in isolation, as an expression of depression, as a fluctuation in mood, or in the context

of motor and cognitive symptoms. Specifically, the clinical differentiation of apathy from the affective symptoms of depression and executive dysfunctions, such as in planning and organizing, is challenging [126].

Although fatigue in PwPD is often associated with daytime sleepiness, depression, and apathy as a comorbidity, it can and should be separated from these as an independent phenomenon by, among other things, obtaining a careful medical history [127, 128].

Questions to be asked when obtaining a patient’s medical history to assess affective disorders

Obtaining a careful medical history plays a crucial role in detecting affective disorders during routine clinical practice. On one hand, there is limited time and personnel resources for the use of (semi-)structured clinical interviews or standardized scales as self-evaluation or other-evaluation with which affective disorders can be recorded or their severity evaluated. On the other hand, scales should not be used as a sole instrument for diagnosing affective disorders. Notably, depression cannot be diagnosed solely based on a score, as high depression scores can occur with somatic symptoms despite the absence of core symptoms of depression (e.g., sadness, loss of interest, anhedonia), and low scores can occur despite the presence of severe depressive symptoms if somatic or vegetative problems are absent. All depression scales contain items on symptoms that can be associated with depression, in addition to apathy, cognitive impairment, and parkinsonism. This applies in particular to the Hamilton Depression Rating Scale (HAM-D) and, to a lesser extent, the Montgomery–Asberg Depression Rating Scale (MADRS) and Beck Depression Inventory (BDI) [128].

Furthermore, scales generally record patients’ subjective state of health over the preceding 1 or 2 weeks. In addition, they do not consider the objective clinical condition of patients with fluctuating motor function. This means that PwPD may perceive their own condition differently when they are in an off-status than when they are in an on-status [129]. Off-periods can also be associated with fluctuating non-motor symptoms, depression, anxiety, and delusions [121, 129, 130].

When obtaining a medical history, the question arises as to which questions are suitable for the sensitive and specific assessment of affective disorders. Based on the above-mentioned evidence and considerations, the authors suggest the following questions for the assessment of affective disorders, per expert consensus. The number and selection of questions are applicable to, sensible in, and practicable to everyday clinical practice. When obtaining a medical history, patients should be in a clinical on-status, which should be documented using the motor examination of the UPDRS-III if necessary. In a recognizable clinical off-status, medication

should be administered first, or the result should be documented as “conditional” and checked when the patient is in an on-status. An external medical history can provide valuable information for supplementary diagnostics. This applies in particular to the presence of cognitive disorders in PwPD.

Recommendations for questions to be asked when obtaining a medical history to assess affective disorders (new)

Affective disorders—general: The two questions from the “two-question test” should be asked

Have you often felt down, sad, depressed, or hopeless in the last month?

In the past month, have you had significantly less pleasure and joy in doing things that you normally enjoy?

Depression

Have you ever suffered from a depressive disorder, and have you ever received antidepressant treatment?

Do you sleep well or sleep through the night?

How is your appetite?

Do you often feel an inner restlessness?

Are you still able to enjoy things?

Do you have difficulty concentrating or staying alert?

Does your mood change when your medication wears off or stops working?

Apathy and mood swings

Are you still interested in activities, things, or people?

Do you sleep a lot during the day?

Do you do things with friends or family?

Does your drive and motivation change when your medication wears off or stops working?

Anxiety disorders and mood swings

Are you often anxious?

Do you often feel an inner restlessness or tenseness?

Are you prone to panic attacks?

Are you afraid of being around people?

Do you experience feelings of anxiety when the effect of your medication decreases or wears off?

Fear of progression

Are you afraid of the future course of your disease?

Are you pessimistic, despondent, or hopeless about the future when you think about the further course of your Parkinson's disease?

Fatigue and mood swings

Do you often feel tired or exhausted, despite getting enough sleep?

Do you often lack the energy to do things?

Do you sleep a lot during the day?

Do you have difficulty concentrating or staying alert?

Do you feel exhausted when your medication wears off or fails to work?

Level of consensus: 93.4%, strong consensus

Scales and questionnaires

In addition to data derived from systematic reviews and previously published guidelines, the recommendations of

the MDS were considered. Besides relevant information that is gathered from a self- and externally obtained medical history, various general non-motor symptom scales or relevant subscales and the generic Neuropsychiatric Inventory (NPI) can be considered. However, the assessment of the affective symptoms in all these scales is based on individual or only a few items, and in some cases, no separate scores for the specific affective disorders are available. The gold standard for diagnosing affective disorders in PwPD according to the MDS is to conduct a (semi-)structured interview based on the criteria of the *Diagnostic and Statistical Manual of Mental Disorders* fifth edition (DSM-5, i.e., with the Structured Clinical Interview for DSM-5 Disorders [SCID-5]). However, this standard is rarely implemented in clinical settings. If there are signs of affective disorders, several scales are available that assess the specific types of these disorders, including self-assessment questionnaires and external assessment scales. To differentiate the severity of depressive disorders, only specific depression scales seem valuable. Due to the clinical relevance of this symptom, these guidelines also suggest a questionnaire for the assessment of fear of progression. The idea of a regular screening package to monitor possible affective disorders in PwPD was raised, e.g., by sending a questionnaire package by post in advance of a routine neurological examination.

Recommendations for scales and questionnaires to assess affective disorders (new)

The following scales and questionnaires are recommended

Initial diagnosis of affective disorders: General scales

Scales for the assessment of non-motor symptoms (here, specific items or subscales for affective disorders) can be used

- Movement Disorders Society Unified Parkinson's Disease Rating Scale, Part 1 (MDS-UPDRS-I)
- Movement Disorders Society Non-Motor Rating Scale (MDS-NMS)
- Non-Motor Symptom Scale (NMSS)
- Non-Motor Symptom Questionnaire (NMSQ)

Initial diagnosis of affective disorders: Specific scale

The corresponding items of the following instrument might be used:

- Neuropsychiatric Inventory (NPI)

Specific scales

For the specific diagnosis of affective disorders, specific scales validated for PwPD should be used. The following scales are suitable for this purpose, are frequently used in everyday clinical practice, and are recommended by the authors

Depression

- Beck Depression Inventory (BDI-II)
- Geriatric Depression Scale (GDS-15)
- Two-question test

Anhedonia

- Snaith-Hamilton Pleasure Scale (SHAPS)

Apathy

- Apathy Evaluation Scale (AES)

Anxiety

- Hospital Anxiety and Depression Scale (HADS)

Fatigue

- Fatigue Severity Scale (FSS)

Fear of progression (might be used)

- Short form of the Fear of Progression Questionnaire (FoP-Q)

Depression: Assessment of the degree of severity (might be used)

- BDI-II

Level of consensus: 100%, strong consensus

The non-pharmacological treatment of affective disorders in people with Parkinson's disease

General remarks

In this chapter, the authors considered only interventions that, according to current German routine clinical practice, physicians may prescribe for PwPD. These include psychotherapy, physical interventions, and occupational therapy. As data on occupational therapy were insufficient, no recommendations could be derived therefrom.

Depression

Regarding psychotherapy, recommendations were based on two meta-analyses that analyzed the effects of CBT [131, 132] and one meta-analysis that considered the effects of both CBT and psychodynamic approaches [133] in PwPD. All these analyses showed significant effects of psychotherapy on depression compared to control groups. The effects of psychotherapy might even have been larger than the effects of antidepressants [134]. Notably, a subgroup analysis of one meta-analysis [133] found that treatments of more than 6 weeks are more effective than shorter treatment periods. A subgroup analysis of another meta-analysis confirmed that longer interventions (here, 8 or more weeks) have a greater effect than shorter intervention durations [132]. This latter study also indicated that individual interventions are significantly more effective than group interventions in treating depression in PwPD, while the effects of online and offline interventions do not differ.

Two overarching meta-analyses that included studies on different physical interventions in PwPD [135, 136] and several meta-analyses on specific physical interventions (e.g., dance, resistance training) [137–142] demonstrated convincing evidence for their effectiveness on depressive symptoms in PwPD. Furthermore, the German guidelines for unipolar depression (2022) [7] recommend motivating patients with a depressive disorder to engage in physical activity, ideally within a group; they should also be motivated to participate in structured and supervised physical

training, and they should be supported in its implementation. Notably, there should be no contraindication for the specific type of physical exercise. and in PwPD, the risk of falling should be given special consideration when choosing and intensifying physical activity.

Recommendations for non-pharmacological interventions to treat depressive symptoms (new)

Cognitive behavioral therapy should be offered

Physical interventions should be offered

Level of consensus: 100%, strong consensus

Apathy

No meta-analysis or RCT on psychotherapeutic interventions for the treatment of apathy in PwPD was identified. Furthermore, apathy has rarely been defined as an outcome in physical intervention studies. Two meta-analyses [138, 139] that both included the same two RCTs ($N=62$ PwPD) that defined apathy as an outcome found no significant effect of dance therapy on apathy scores compared to active control groups. However, an RCT with $N=20$ PwPD showed a positive effect of Nordic walking on apathy symptoms compared to a passive control group [143]. An RCT that investigated the effectiveness of aerobic training compared to a stretching program among $N=35$ PwPD was unable to show the superiority of either training program [144]. The comparison of a physical intervention held in a group format and individual format without supervision among $N=30$ PwPD was also unable to show the superiority of one type of training in relation to apathy symptoms [145].

Based on the one RCT that provided evidence for a possible effect of physical interventions for the treatment of apathetic symptoms in PwPD, the following recommendation was proposed.

Recommendations for non-pharmacological interventions to treat apathy (new)

Physical interventions might be offered

Level of consensus: 100%, strong consensus

Anxiety

Two recent meta-analyses [131, 132] examining the effects of psychotherapy on anxiety were identified; both considered only CBT. Zhang et al. [131], who included five RCTs and one non-RCT, with $N=163$ PwPD in their meta-analysis found a significant moderate effect of CBT offered in different formats (individual vs. group therapy, analog vs. telephonic therapy) compared to the active and passive control groups. In the meta-analysis published in 2021 by Luo et al.

[132], ten studies with $N=383$ PwPD were included in the comparison of CBT and control groups, showing a significant and large effect in favor of CBT. Subgroup analyses also demonstrated that interventions over a period of at least 10 weeks have the greatest effect on reducing anxiety. There were no differences between the effects of analog and digital formats. However, individual therapy proved to be superior to group therapy. Notably, in the German S3 guidelines on the treatment of anxiety disorders [8], CBT is given the highest recommendation for the treatment of generalized anxiety disorder, panic disorder or agoraphobia, specific phobias, and social anxiety disorder. No meta-analysis or RCT examining the effects of psychotherapy on fear of progression was identified.

Regarding physical interventions, a recent large-scale network meta-analysis [136] that considered 250 studies with $N=13,011$ PwPD was identified. Thirteen of these studies with $N=757$ PwPD included anxiety symptoms as an outcome. The network meta-analysis only found yoga to be significantly superior to the active and passive control groups. However, this result was based on only one yoga study. According to the authors of another recent meta-analysis [146] that focused specifically on the effects of physical interventions on anxiety symptoms in PwPD, currently available data were insufficient to derive any recommendations.

Based on the given evidence, the following recommendation was formulated.

Recommendations for non-pharmacological interventions to treat anxiety (new)

Cognitive behavioral therapy should be offered

Level of consensus: 100%, strong consensus

As there is an overlap between anxiety disorders and fear of progression, the use of CBT for severe fear of progression was also discussed in the expert meetings. Here, RCTs with other target groups (e.g., people with cancer) that showed positive effects of CBT on fear of progression were also considered (e.g., [147]). The recommendation was formulated as follows.

Recommendations for non-pharmacological interventions to treat fear of progression (new)

Cognitive behavioral therapy might be offered

Level of consensus: 100%, strong consensus

Fatigue

Data on the effects of psychotherapeutic approaches for fatigue management have not been convincing. In their meta-analysis, Luo et al. [132] included two studies on CBT compared to active control groups with $N=32$ PwPD and

were unable to identify a significant effect on fatigue symptoms. Jiang et al. [148] included only one RCT with $N=12$ PwPD in their meta-analysis, which investigated a combination of CBT and light therapy compared to a placebo group, but found no positive effects on fatigue symptoms. A recent RCT that Bogosian et al. [149] conducted also did not demonstrate any significant effects of a mindfulness-based intervention on the fatigue symptoms of PwPD compared to a passive control group. Therefore, no recommendation for psychotherapy as a treatment for fatigue was given.

Only two RCTs with $N=57$ PwPD participating in physical interventions could be included in the 2015 Cochrane review [150], whereby no positive effect on fatigue symptoms could be determined. Two meta-analyses on specific physical intervention approaches (i.e., mind–body interventions and dance therapy) only included three ([138]; $N=74$ PwPD) and two ([138]; $N=58$ PwPD) RCTs, respectively, and could not show the superiority of physical interventions over control groups. A recent meta-analysis [148] with four RCTs and $N=100$ PwPD participating in different physical intervention approaches showed a trend for the superiority of the intervention over control groups. Another recent meta-analysis [151] was able to draw on 30 RCTs on different drug and non-drug treatment approaches. Eight studies with $N=324$ PwPD could be considered for meta-analysis on physical interventions in comparison with control groups. There was shown a significant but small effect of physical interventions on fatigue symptoms in PwPD compared to the active and passive control groups. No clear recommendations regarding duration, frequency and type of intervention can be drawn from the existing evidence. Based on these considerations, the following recommendation was given.

Recommendations for non-pharmacological interventions to treat fatigue (new)

Physical interventions should be offered

Level of consensus: 100%, strong consensus

Table 2 Overview of recommendations for non-pharmacological treatment of affective disorders in PwPD

	Cognitive behavioural therapy	Physical intervention
Depression	+++	+++
Apathy	–	+
Anxiety	+++	–
Fear of progression	+	–
Fatigue	–	+++

+++ should be offered; + might be offered; – no recommendation

An overview of the recommendations for non-pharmacological intervention approaches to treat affective disorders in PwPD is given in Table 2.

The pharmacological treatment of affective disorders in people with Parkinson's disease

Dopaminergic therapy in the treatment of affective disorders

The optimization of dopaminergic replacement therapy is an essential factor in the treatment of non-motor fluctuating and non-fluctuating, affective symptoms in PwPD [121, 152].

Depression

An RCT ($n = 287$ PwPD were randomized 1:1 to a treatment with pramipexole or a placebo) showed a significant improvement in BDI scores at 12 weeks in the pramipexole group compared with the placebo group, with an acceptable safety profile [153]. Three meta-analyses showed an antidepressant effect of pramipexole in PwPD [154–156]. In an RCT involving 44 PwPD, pramipexole and citalopram led to a comparable reduction in BDI scores after 8 weeks [157]. An RCT testing the antidepressant effect of rotigotine in 80 PwPD (randomized 1:1 to a placebo group) did not show superiority of the antidepressant [158]. Two meta-analyses, including eight and 10 RCTs, respectively, showed a positive effect of rotigotine on depressive symptoms in PwPD [159, 160]. Overall, there has been limited evidence for the effects of priribedil on depressive symptoms in PwPD.

Anhedonia

No RCT with anhedonia as a primary outcome could be found. Anhedonia is thought to reflect a hypodopaminergic state in PwPD [161]. A single dose of L-dopa improves anhedonia in patients with advanced PD [152]. Observational studies and secondary analyses have also reported beneficial effects of rotigotine, pramipexole, and priribedil on anhedonia symptoms [162–164].

Mood swings

No RCT with mood swings as a primary outcome could be found. As with motor fluctuations, experts recommended stable plasma L-dopa levels and non-ergot dopamine agonists [165].

Apathy

Apathy has been shown to improve with L-dopa therapy [166]. Twenty-two PwPD were treated with pramipexole,

ropinirole, or L-dopa, and pramipexole was shown to have a better effect on symptoms of apathy than ropinirole and L-dopa [167]. A meta-analysis and several case reports and observational studies showed a positive effect of pramipexole and rotigotine on apathy symptoms [162–164, 168]. A placebo-controlled RCT showed that priribedil can be used successfully for the treatment of symptoms of apathy after deep brain stimulation of the subthalamic nucleus [168]. An RCT for the treatment of apathy in de novo PD patients did not show superiority of ropinirole [169].

Anxiety disorders

Studies have indicated that anxiety symptoms associated with mood swings can be successfully treated with L-dopa and non-ergot dopamine agonists. This has been shown in case reports, observational studies, and two meta-analyses [170–172]. Trials defining anxiety as a non-fluctuating symptom as their primary outcome are lacking, though.

Fatigue

In the ELLDOPA study, 361 de novo PwPD received a placebo or L-dopa at various doses for 40 weeks. The L-dopa groups showed significantly less progression in fatigue during the study [173]. This finding is consistent with the observation that L-dopa reduces fatigue [174]. Two studies (including one RCT) reported an improvement in fatigue with rotigotine [162, 175]. Two meta-analyses, including 10 and 8 studies, respectively, with a total of 1800 PwPD reported a positive treatment effect of rotigotine on fatigue symptoms [159, 160]. Pramipexole's effect on fatigue symptoms has been less thoroughly studied, but available studies have provided evidence for both improvements and worsening [176, 177].

Recommendations for dopaminergic medication to treat affective disorders in people with Parkinson's disease (new)

Depressive disorders

An optimal dopaminergic medication should be used to treat depressive disorders. Pramipexole should be used if dopamine agonist therapy is individually feasible. The dopamine agonist rotigotine might be used as a secondary treatment

Anhedonia

The optimal dopaminergic medication of levodopa and/or rotigotine, pramipexole, or priribedil should be used to treat anhedonia

Mood swings

An optimal dopaminergic medication should be used for the treatment of mood swings. Non-ergot dopamine agonists might be used. No dopamine agonist has been shown to be superior, though

Apathy

An optimal dopaminergic medication should be used to treat apathy. In addition, the dopamine agonists pramipexole, rotigotine, or piribedil might be used if dopamine agonist therapy is individually feasible

Anxiety disorders

For anxiety disorders with mood swings, the optimal dopaminergic medication should be used, and a non-ergot dopamine agonist should be used if dopamine agonist therapy is individually feasible

Dopaminergic therapy cannot be used to treat persistent anxiety without mood swings, though

Fatigue

An optimal dopaminergic medication should be used to treat fatigue. In addition, rotigotine might be used if dopamine agonist therapy is individually feasible

Level of consensus: 100%, strong consensus

An overview of the recommendations for the dopaminergic treatment of affective disorders in PwPD is given in Table 3.

Non-dopaminergic therapy in the treatment of affective disorders: General remarks

In addition to the dopaminergic system, other neurotransmitter systems are also involved in the evolution of affective disorders in PwPD. Serotonergic degeneration has already been found to play a prominent role in de novo PwPD [178, 179]. The role of the glutamatergic system as a modulator of emotions has also been discussed [180]. The national guidelines for unipolar depression [7] point out that patients with severe depression (“major depression”) in particular benefit from antidepressant drug therapy, while this effect is not so clear in people with mild depression (“minor depression”) or dysthymic disorder, and it is unclear whether this finding can also be applied to PwPD suffering from depression. In addition, most PwPD with signs and symptoms of depression do not fulfill the criteria for major depression [108].

Depressive and anxiety disorders

The previous guidelines for PD, published in 2016 [181], recommended tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), venlafaxine, and omega-3 fatty acids for the treatment of major depression in PwPD. As a basis, a meta-analysis showed no difference in the treatment of depression in PwPD between SSRI and a placebo and TCA [182]. A systematic review [183] reported that nortriptyline (two RCTs [184, 185]) and desipramine (one RCT [186]) are probably effective for the treatment of depressive disorders in PwPD. One study showed that nortriptyline, but not paroxetine, is effective compared with a placebo in improving depressive symptoms in PwPD in an 8-week RCT [184]. In the 16-week blinded extension phase, relapse was significantly more frequent with the placebo than with nortriptyline and paroxetine [186, 187]. In the RCT, the antidepressant effect of desipramine occurred earlier (after 14 days) than that of citalopram (after 30 days) [186]. Another RCT without a placebo arm showed that low-dose amitriptyline and sertraline have comparable antidepressant effects [188]. A 4-week RCT with 23 PwPD showed that treatment with 50 mg of 5-hydroxytryptophan (5-HTP), which is an intermediate metabolite of L-tryptophan in the production of serotonin, results in significant improvements in depressive symptoms (using the HAM-D) compared with a placebo. There was, however no effect of 5-HTP on symptoms of apathy [189]. A 12-week RCT with omega-3 fatty acids showed a significant reduction in depression scores compared with a placebo [190]. Supplementary Table 2 shows an overview of prospective controlled studies on treatment with non-dopaminergic substances in PwPD with depression. Notably, the study period has been short in most studies, and the number of cases in the study populations analyzed has been small.

Antidepressants with anticholinergic properties are associated with an increased risk of deterioration in cognitive

Table 3 Overview of recommendations for dopaminergic treatment of affective disorders in PwPD

	Individually optimized treatment with levodopa	Non-ergot dopamine agonists (if individually feasible, monotherapy or add on with levodopa)			
	Levodopa	Pramipexole	Rotigotine	Piribedil	Ropineroles
Depression	+++	+++	+	–	–
Anhedonia	+++	+	+	+	–
Apathy	+++	+	+	+	–
Anxiety with affective fluctuations	+++	+	+	+	+
Anxiety without affective fluctuations	–	–	–	–	–
Fatigue	+	–	+	–	–

+++ should be offered; + might be offered; – no recommendation

function, triggering hallucinations or psychosis, increased constipation, and an increased cardiovascular risk, particularly in elderly and cognitively impaired PwPD, and should only be used with caution [121]. The noradrenaline reuptake inhibitor desipramine demonstrates both efficiency as an antidepressant [186] and a smaller anticholinergic and antihistaminic effect among TCAs. Desipramine is not commercially available in the EU but can be imported (as nortriptyline) from international pharmacies in drug dosages of 10, 25, 50, 100, or 150 mg. Nortriptyline, the TCA with the best data among PwPD, acts mainly as a serotonin and noradrenaline reuptake inhibitor (SNRI), in addition to its sedative effect due to its additional antagonization of H1 and 5-HT_{2A} receptors [191]. However, nortriptyline has a high affinity for antagonizing muscarinic acetylcholine receptors and, therefore, has a strong anticholinergic effect [191]. In addition, there is a potential cardiotoxic effect due to the sodium or calcium channel blocking action [192] of nortriptyline, so its use can be problematic in PwPD. SSRIs (citalopram) and SNRIs (slow-release venlafaxine) have demonstrated antidepressant effects in clinical trials [157, 193] and may have less side effects compared with TCAs. The combination of an SSRI with an irreversible monoamine oxidase-B (MAO-B) inhibitor like selegiline is not recommended because of the risk of developing serotonergic syndrome [194]. The use of trazodone as a dual-acting serotonergic agent, with its presynaptic inhibition of serotonin reuptake and postsynaptic blockade of 5-HT_{2A} receptors, strong affinity for central alpha-1 receptors, weak antagonistic affinity for H1 receptors, and lack of anticholinergic activity [195], also appears feasible in the treatment of depression in PwPD. Trazodone has a sedative effect that may be beneficial in PwPD with sleep problems. Given the limited clinical data, though, trazodone is a second-line recommendation [196, 197].

Unchanged from the previous German PD guidelines from 2016 [181], the authors recommend venlafaxine and desipramine for the treatment of major depression in PwPD, as these drugs have been clinically investigated and have acceptable safety profiles. The authors recommend treating moderate depressive disorders in PwPD according to the clinical phenotype, distinguishing between PwPD with psychomotor retardation, agitation, or the coexistence of other influencing factors like pain, salivation, cognitive impairment, and sleep disturbances.

There were no trials that investigated the effect of medication on anxiety in PwPD without underlying depression. Clinical trials in psychiatric populations have shown a beneficial effect of citalopram on anxiety disorders [198, 199]. Although the clinical symptoms of PwPD do not correspond to those of a psychiatric population, a trial of citalopram for the treatment of anxiety symptoms can be recommended for PwPD.

Mirtazapine is a noradrenergic and specific 5-HT_{1A}-mediated serotonergic as well as 5-HT₂ and 5-HT₃ receptor blocking substance. Numerous in vitro and in vivo investigations have demonstrated not only the antioxidant and anti-inflammatory properties of Mirtazapine but also anti-inflammatory and anti-apoptotic effects. Due to the pathophysiology of PD, this might be of special interest and be advantageous in this target group. Because Mirtazapine can trigger REM sleep behavior disorder (RBD) likely due to its lacking anticholinergic activity it should not be applied in concomitant RBD [200], which is common in PD. The HT_{2a/c} antagonistic effect is likely to be advantageous in PD patients with psychotic symptoms. Mirtazapine has antihistamine sedative properties due to its histamine H₁ receptor blocking effect and shows a good safety and tolerability profile [201–203]. Therefore, it is broadly and preferentially used by Parkinson specialists in Germany in depressed PwPD especially with comorbid insomnia [204] and without RBD.

Overall, four reviews suggest Mirtazapine in PwPD and moderate depression with concomitant night-time agitation, anxiety, restlessness, sleep disturbances/insomnia and/or hallucinations/psychosis [197, 203, 205, 206]. It has to be considered, that these suggestions are based on the pharmacological profile of Mirtazapine and with respect to the recommendation for PwPD with depression and psychosis on four case reports [207–210].

The following recommendations not only involved an evaluation of the results of RCTs but also considered the efficacy profiles of antidepressants, which have been reported in clinical studies of psychiatric patient populations. The authors evaluated these findings within the clinical context of PD.

Recommendations for non-dopaminergic drug therapy to treat depressive disorders (updated)

Severe depression might be treated with

- Venlafaxine 75–225 mg
- Desipramine 25–200 mg

Moderate depression might be treated according to its clinical phenotype

Dominance of psychomotor retardation

- Venlafaxine 75–150 mg
- Citalopram 20–40 mg
- Sertraline 50–100 mg

Dominance of agitation, anxiety, restlessness, or sleep disturbances

- Mirtazapine 15–45 mg (not for REM sleep behavior disorder)
- Trazodone 100–200 mg

Comorbidities of pain, salivation, cognitive impairment, or sleep disturbances

- Amitriptyline 10–75 mg retard

Level of consensus: 100%, strong consensus

Recommendations for non-dopaminergic drug therapy to treat anxiety or panic disorders (new)

Anxiety or panic disorder

- Non-dopaminergic drugs to treat anxiety and panic disorders have not been sufficiently tested

Citalopram 20–40 mg might be used

Level of consensus: 95%, strong consensus

Apathy

Safinamide works by inhibiting MAO-B and abnormal glutamate release. The efficacy of safinamide in non-motor PD symptoms, including affective disorders, was investigated in a post-hoc analysis of data from two RCTs. Safinamide showed a significant positive effect on quality of life (tested using the Parkinson's Disease Questionnaire's [PDQ-39] emotional well-being subscale) and depressive symptoms (tested using the GRID–Hamilton Depression Rating Scale [GRID–HAM-D]) at 6 and 24 months compared to a placebo [211, 212]. A prospective, single-armed, open-label (uncontrolled) study of the efficacy of safinamide on non-motor symptoms showed a significant improvement in mood and apathy symptoms over 6 months among 44 PwPD, with good overall tolerability [212]. Whether this effect is driven by a non-dopaminergic modulation of glutamatergic hyperactivity or by primarily dopaminergic reversible MAO-B inhibition remains unanswered, though.

Anhedonia

There were no RCTs on the treatment of anhedonia.

Fatigue

Methylphenidate (30 mg per day) showed a significant reduction in the two primary outcomes (tested using the FSS and Multidimensional Fatigue Inventory) of an RCT with 36 PwPD [213]. This positive result was tempered by two factors. First, a group analysis (verum vs. placebo) was not performed, and second, no statistical correction for multiple outcomes was performed. The effect of modafinil on fatigue symptoms in PD was investigated in two RCTs [214, 215]. Given the inclusion of small sample sizes ($n = 19$ and $n = 13$) and undefined primary outcomes, modafinil could not be recommended [181, 211]. Safinamide was tested as an add-on therapy in 39 PwPD to treat fatigue over 24 weeks. The results showed an improvement in fatigue compared with the baseline using the FSS and Parkinson's Fatigue Scale-16 (PFS-16). Specifically, 46% (FSS) and 41% (PFS-16) of PwPD were fatigue-free at the end of the study [216].

Recommendations for non-dopaminergic drug therapy to treat apathy, anhedonia, and fatigue (new)

Apathy might be treated using

- Venlafaxine 75–225 mg retard
- Nortriptyline 25–150 mg

Level of consensus: 96.2%, strong consensus

Anhedonia

- There is no evidence for the use of non-dopaminergic medication for the treatment of anhedonia in PwPD

Level of consensus: 100%, strong consensus

Fatigue

- Non-dopaminergic drugs have not been sufficiently tested
- Modafinil 100–200 mg or safinamide 100 mg might be used

Level of consensus: 96.2%, strong consensus

An overview of the recommendations for the non-dopaminergic treatment of affective disorders in PwPD is given in Table 4.

Discussion

This guideline article summarized evidence for and expert opinions on diagnostic and therapeutic practices in the management of cognitive impairment and affective disorders in PwPD, and the derived recommendations for the German health care system were outlined.

Since the diagnosis of cognitive impairment in PwPD should be based on assessments with sufficient diagnostic properties [15], these guidelines included recommendations for suitable German global cognitive scales and tests to assess specific cognitive functions, as well as ADL assessment measures, to support the diagnosis of PD–MCI and PDD. However, more studies are needed to evaluate the discriminatory diagnostic power of (the German versions of) the instruments. To treat PD–MCI, cognitive training and physical interventions are recommended, whereas currently available evidence does not show that pharmacological treatment comprising AChEIs and memantine is sufficiently efficacious. In general, double-blinded RCTs with people with PD–MCI in multicenter studies should be performed to obtain more knowledge about the optimized intensity and duration of cognitive training. For PDD therapy, the AChEI rivastigmine and the off-label use of donepezil, as well as cognitive stimulation and reminiscence therapy as additional non-pharmacological treatment approaches, are recommended. Notably, there is currently a lack of therapists and prescriptions for the non-pharmacological treatment of cognitive symptoms in PwPD in Germany. The potential of food supplements and herbal therapeutics as a treatment option for cognitive impairment in PwPD needs further investigation in double-blinded, placebo-controlled RCTs.

Table 4 Overview of recommendations for non-dopaminergic treatment of affective disorders in PwPD

	Venlafaxine	Desipramine	Citalopram	Sertraline	Mirtazapine	Trazodone	Amitriptyline	Nortriptyline	Modafinil	Safinamide
Major depression	+	+								
Moderate depression with comorbidity of ...	+		Psychomotor retardation	+	Agitation	+	+			
				Psychomotor retardation			Sleep disturbance, hypersalivation or pain only in cognitively intact patients			
Apathy	+							+		
Anxiety			+							
Fatigue									+	+

+ might be offered; – no recommendation

To date, there is a lack of knowledge about to what extent non-pharmacological and pharmacological interventions can prevent or delay a conversion to PD–MCI and PDD and, therefore, whether these interventions are effective to modulate cognitive deterioration in PwPD.

The guidelines provide a new outlook for obtaining medical histories and using scales to diagnose and track affective disorders in PwPD. Further, in addition to the update to dopaminergic and non-dopaminergic treatments, non-pharmacological treatment options like CBT and physical interventions could now be included and recommended. Despite their prevalence and impact on the quality of life of PwPD and that of their relatives, affective disorders are largely underdiagnosed [4] and, consequently, undertreated. Therefore, these recommendations may serve as the basis for implementing this largely neglected aspect into clinical diagnostic and treatment routines for PwPD. Here, the limited availability of psychotherapists and providers of physical interventions for PwPD in Germany is a challenge. Furthermore, for most non-pharmacological interventions, evidence is still too rare to derive more detailed recommendations regarding, e.g., duration and frequency of the treatment. Defining these treatment regimes with best effects for specific outcomes should be subject to further studies and could thus be integrated in future guidelines. This also holds true for further intervention types with potential benefits which could not be considered here.

No data are currently available on the implementation of the outlined recommendations in Germany. At best, guideline recommendations are based on the results of RCTs, but they cannot cover all the factors that influence the treatment of patients. Therefore, there are often medical conditions in the prevention, diagnosis, and treatment stages that cause the practitioner to deviate from the guidelines. The following sections outline some of the daily considerations for practice, in addition to guideline issues.

When diagnosing cognitive impairment in PwPD, competing causes must be considered on an individual basis. These include coexisting vascular cerebral damage, Alzheimer's disease, cognitive disorders as a sign of depression, vitamin deficiency (B12, folic acid), substance abuse, metabolic disorders, and normal pressure hydrocephalus. In addition to a medical history, a physical examination, and neuropsychological testing, serological and biochemical tests of the blood are often required, in addition to the infrequent need for cerebrospinal fluid analysis. The anticholinergic activity of both PD and non-PD medications is of particular importance given its negative effect on cognitive functioning [217]. This is often the case with drugs used to treat non-motor symptoms (antidepressants, antipsychotics, bladder dysfunction therapy) and drugs not associated with PD therapy (antihistamines, anticonvulsants, opioids, glucocorticoids). The potency of drugs' cognitive side effects is

determined by the affinity of the muscarinic receptor type, pharmacokinetics, lipophilicity, and thus, potency of its crossover of the blood–brain barrier. A review summarizing drugs with an anticholinergic effect that also negatively affect cognition is available [218].

With neuropsychiatric symptoms, several differential diagnoses need to be considered, including anemia, hypothyroidism, metabolic disorders, or vitamin deficiencies. Sleep disorders should also be considered in differential diagnoses, especially with apathy and fatigue. The sometimes difficult clinical task is then to distinguish cognitive fatigue from physical fatigue. Sleep disturbances may lead to both cognitive and physical symptoms of fatigue. Since there is little correlation between subjective and objective measures of sleep in PwPD [219], the patient's medical history is often not sufficiently informative.

Future research will have to investigate the utilization and feasibility of the suggested guidelines in clinical practice. Due to limited time and personnel resources and/or a lack of awareness of cognitive and affective disorders in PwPD, both the use of standardized diagnoses of these symptoms and prescriptions of (especially non-pharmacological) therapies constitute a major challenge.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00415-024-12503-0>.

Acknowledgements The manuscript has been supported by the German Parkinson Guideline Group: Prof. Dr. med. Mathias Bähr, Göttingen; Dr. med. Jos Becktepe, Kiel; Prof. Dr. med. Daniela Berg, Kiel; Priv.-Doz. Dr. med. Kathrin Brockmann, Tübingen; Prof. Dr. med. Carsten Buhmann, Hamburg; Prof. Dr. med. Andrés Ceballos-Baumann, München; Prof. Dr. med. Joseph Claßen, Leipzig; Priv.-Doz. Dr. med. Cornelius Deuschl, Essen; Prof. Dr. med. Günther Deuschl, Kiel; Prof. Dr. med. Richard Dodel; Prof. Dr. med. Georg Ebersbach, Beelitz-Heilstätten; Prof. Dr. med. Carsten Eggers, Bottrop; Prof. Dr. med. Thilo van Eimeren, Köln; Ass. Prof. med. Dott.ssa mag. Dr. Alessandra Fanciulli, Innsbruck (A); Priv.-Doz. Dr. phil. Bruno Fimm, Aachen; Dr. Ann-Kristin Folkerts, Köln; Madeleine Gausepohl, Bad Segeberg; Prof. Dr. med. Alkomiet Hasan, Augsburg; Dr. med. Wiebke Hermann, Rostock; Prof. Dr. med. Rüdiger Hilker-Roggendorf, Recklinghausen; Prof. Dr. med. Günter Högl, München; Priv.-Doz. Dr. med. Matthias Höllerhage, Hannover; Prof. Dr. med. Franziska Hopfner, München; Prof. Dr. med. Wolfgang Jost, Ortenau; Prof. Dr. rer. nat. Elke Kalbe, Köln; Prof. Dr. med. Jan Kassubek, Ulm; Prof. Dr. med. Stephan Klebe, Essen; Prof. Dr. med. Christine Klein, Lübeck; Priv.-Doz. Dr. med. Martin Kliez, Hannover; Priv.-Doz. Dr. med. Thomas Kögl, München; Prof. Dr. med. Andrea Kühn, Berlin; Prof. Dr. med. Paul Krack, Bern (CH); Priv.-Doz. Dr. med. Florian Krismer, PhD, Innsbruck (A); Prof. Dr. med. Dr. Gregor Kuhlenbäumer, Kiel; Prof. Dr. med. Johannes Levin, München; Dr. rer. nat. Inga Liepelt-Scarfone, Tübingen/Stuttgart; Prof. Dr. med. Paul Lingor, München; Dr. med. Kai Loewenbrück, Großschweidnitz; Dr. med. Matthias Löhle, Rostock; Prof. Dr. med. Stefan Lorenzl, Agatharied; Dr. med. Sylvia Maaß, Murnau und München; Prof. Dr. med. Walter Maetzler, Kiel; Regina Menzel, Heidelberg; Prof. Dr. med. Philipp T. Meyer, Freiburg i.B.; Prof. Dr. med. Brit Mollenhauer, Kassel; Prof. Dr. med. Manuela Neumann, Tübingen; Prof. Dr. med. Per Odin, Lund; Prof. Tiago Outeiro, PhD, Göttingen; Priv.-Doz. Dr. med. Monika Pötter-Nerger, Hamburg; Priv.-Doz. Dr. med. René Reese, Rostock; Prof. Dr. med. Kathrin

Reetz, Aachen; Prof. Dr. med. Olaf Rieß, Tübingen; Dr. med. Viktoria Ruf, München; Prof. Dr. med. Anja Schneider, Bonn; Priv.-Doz. Dr. med. Christoph Schrader, Hannover; Prof. Dr. med. Alfons Schnitzler, Düsseldorf; Prof. Dr. med. Klaus Seppi, Innsbruck/Kufstein (A); Priv.-Doz. Dr. med. Friederike Sixel-Döring, Kassel; Prof. Dr. med. Alexander Storch, Rostock; Prof. Dr. med. Lars Tönges, Bochum; Prof. Dr. med. Claudia Trenkwalder, Kassel/Göttingen; Prof. Dr. med. Thilo van Eimeren, Köln; Prof. Dr. med. Uwe Walter, Rostock; Prof. Dr. med. Tobias Wächter, Bad Gögging; Prof. Dr. med. Tobias Warnecke, Osnabrück; Prof. Dr. med. Florian Wegner, Hannover; Prof. Dr. med. Christian Winkler PhD, Coppenbrügge; Prof. Dr. med. Karsten Witt, Oldenburg; Prof. Dr. med. Dirk Woitalla, Essen; Prof. Dr. med. Kirsten Zeuner, Kiel.

Funding Open Access funding enabled and organized by Projekt DEAL. The administration of guideline development and the systematic literature search was supported by the German Society of Neurology (DGN). No direct financial funding was provided by the DGN or other commercial entities.

Data availability Systematic literature search data will be shared upon request by any qualified investigator. Data sharing requests should be made in writing to Professor Dr Inga Liepelt-Scarfone (chapter “Cognitive impairment,” inga.liepelt@uni-tuebingen.de, Eberhard–Karls University Tübingen) and Professor Dr Elke Kalbe (chapter “Affective disorders,” elke.kalbe@uk-koeln.de, University of Cologne) and require a formal data sharing agreement with approval from the respective university and the guideline office of the DGN. Data sharing agreements must include details on how the data will be stored, who will have access to the data and the intended use of the data, and agreements about the allocation of intellectual property.

Declarations

Conflicts of interest EK has received grants from the German Ministry of Education and Research, General Joint Committee, Germany, the German Parkinson Society, and STADAPHARM GmbH; honoraria from AbbVie GmbH Germany; memodio GmbH Germany; license fees from Prolog GmbH, Germany. EK is one of the authors of the cognitive intervention series “NEUROvitalis” but receives no corresponding honoraria. AKF has received grants from the German Parkinson Society, the German Alzheimer's Society, the German Parkinson Foundation, STADAPHARM GmbH and the General Joint Committee Germany as well as honoraria from Springer Medizin Verlag GmbH, Heidelberg, Germany; Springer-Verlag GmbH, Berlin; ProLog Wissen GmbH, Cologne, Germany; Seminar- und Fortbildungszentrum Rheine, Germany; LOGOMANIA, Fendt & Sax GbR, Munich, Germany; LOGUAN, Ulm, Germany; dbs e.V., Moers, Germany; STADAPHARM GmbH, Bad Vilbel, Germany; NEUROPSY, St. Konrad, Austria; Multiple Sclerosis Society Vienna, Vienna, Austria; and Gosweiler Foundation, Bern, Switzerland. AKF is one of the authors of the cognitive intervention series “NEUROvitalis” but receives no corresponding honoraria. CB reports fees for lectures and/or honour boards from AbbVie, Bial, Desitin, Kyowa Kirin, Merz, STADA Pharma, TAD Pharma, UCB, Zambon. He has received royalties from Thieme Press and Kohlhammer Press and reports funding from Hilde-Ulrichs-Stiftung für Parkinsonforschung. KW has received funding from the Deutsche Forschungsgemeinschaft (German Research Association) and STADAPHARM GmbH outside the present study. He has received honoraria for presentations/advisory boards/consultations from BIAL, Indorsia, Boston Scientific and STADAPHARM GmbH outside the present study. He has received royalties from Thieme Press and Elsevier Press. He serves as an editorial board member of Wileys “Parkinson's Disease”, “Behavioural Neurology” and PLOSone. ILS reports funding from Bayer AG and travel grants from and travel grants

from Desitin and the German Neurological Society outside the submitted work.

Ethics approval and consent to participate Not applicable

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Macías-García P, Rashid-López R, Cruz-Gómez AJ, Lozano-Soto E, Sanmartino F, Espinosa-Rosso R, González-Rosa JJ (2022) Neuropsychiatric symptoms in clinically defined Parkinson's disease: an updated review of literature. *Behav Neurol* 2022:1213393. <https://doi.org/10.1155/2022/1213393>
- Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021) Parkinson disease-associated cognitive impairment. *Nat Rev Dis Primers* 7:47. <https://doi.org/10.1038/s41572-021-00280-3>
- Duncan GW, Khoo TK, Yarnall AJ, O'Brien JT, Coleman SY, Brooks DJ, Barker RA, Burn DJ (2014) Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. *Mov Disord* 29:195–202. <https://doi.org/10.1002/mds.25664>
- Goodarzi Z, Mele B, Guo S, Hanson H, Jette N, Patten S, Pringsheim T, Holroyd-Leduc J (2016) Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. *BMC Neurol* 16:244. <https://doi.org/10.1186/s12883-016-0754-5>
- Deutsche Gesellschaft für Neurologie e.V. (DGN) (2023) S-2k-Leitlinie Parkinson-Krankheit. Version 8.1. <https://register.awmf.org/de/leitlinien/detail/030-010>. Accessed 9 Apr 2024
- Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e.V. (DGPPN) & Deutsche Gesellschaft für Neurologie e.V. (DGN) (2016) Leitlinie Demenzen Langversion—January 2016. https://register.awmf.org/assets/guidelines/038-013L_S3-Demenzen-2016-07.pdf. Accessed 9 April 2024
- BÄK, KBV, AWMF (2022) S3-Leitlinie Nationale VersorgungsLeitlinie Unipolare Depression. Version 3.2. <https://register.awmf.org/de/leitlinien/detail/nvl-005>. Accessed 9 Apr 2024
- Deutsche Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie e.V. (DGPM) (2021) S3-Leitlinie Behandlung von Angststörungen, Version 2.0. <https://register.awmf.org/de/leitlinien/detail/051-028>. Accessed 9 Apr 2024
- Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C (2017) Cognitive decline in Parkinson disease. *Nat Rev Neurol* 13:217–231. <https://doi.org/10.1038/nrneurol.2017.27>
- Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. *Mov Disord* 23:837–844. <https://doi.org/10.1002/mds.21956>
- Bjornestad A, Pedersen KF, Tysnes OB, Alves G (2017) Clinical milestones in Parkinson's disease: a 7-year population-based incident cohort study. *Parkinsonism Relat Disord* 42:28–33. <https://doi.org/10.1016/j.parkreldis.2017.05.025>
- Svenningsson P, Westman E, Ballard C, Aarsland D (2012) Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. *Lancet Neurol* 11:697–707. [https://doi.org/10.1016/S1474-4422\(12\)70152-7](https://doi.org/10.1016/S1474-4422(12)70152-7)
- Saredakis D, Collins-Praino LE, Gutteridge DS, Stephan BCM, Keage HAD (2019) Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis. *Parkinsonism Relat Disord* 65:20–31. <https://doi.org/10.1016/j.parkreldis.2019.04.020>
- Lerche S, Wurster I, Roben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K (2019) Parkinson's disease: evolution of cognitive impairment and CSF Abeta1-42 profiles in a prospective longitudinal study. *J Neurol Neurosurg Psychiatry* 90(2):165–170. <https://doi.org/10.1136/jnnp-2018-318956>
- Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Mov Disord* 27:349–356. <https://doi.org/10.1002/mds.24893>
- Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M (2007) Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. *Mov Disord* 22:2314–2324. <https://doi.org/10.1002/mds.21844>
- Litvan I, Aarsland D, Adler H, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Tröster AI, Weintraub D (2011) MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. *Mov Disord* 26:1814–1824. <https://doi.org/10.1002/mds.23823>
- Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. *Mov Disord* 22:689–1707. <https://doi.org/10.1002/mds.21507>
- Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatry* 51:745–752. <https://doi.org/10.1136/jnnp.51.6.745>
- Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord* 30(12):1591–1601. <https://doi.org/10.1002/mds.26424>
- Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P, members of the MDS Rating Scales Review Committee (2018) Global scales for cognitive screening in Parkinson's disease: critique and recommendations. *Mov Disord* 33:208–218. <https://doi.org/10.1002/mds.27233>

22. Sulzer P, Becker S, Maetzler W, Kalbe E, van Nueten L, Timmers M, Machetanz G, Streffer J, Salvatore G, Scholz E, Tkaczynska Z, Brockmann K, Berg D, Liepelt-Scarfone I (2018) Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients. *J Neurol* 265:1976–1984. <https://doi.org/10.1007/s00415-018-8942-4>
23. Fengler S, Kessler J, Timmermann L, Zapf A, Elben S, Wojtecki L, Tucha O, Kalbe E (2016) Screening for cognitive impairment in Parkinson's disease: improving the diagnostic utility of the MoCA through subtest weighting. *PLoS ONE* 11:e0159318. <https://doi.org/10.1371/journal.pone.0159318>
24. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ (2010) The MoCA: well-suited screen for cognitive impairment in Parkinson disease. *Neurology* 75:1717–1725. <https://doi.org/10.1212/WNL.0b013e3181fc29c9>
25. Boel JA, de Bie RM, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldmann JG (2022) Level I PD-MCI using global cognitive tests and the risk for Parkinson's disease dementia. *Mov Disord Clin Pract* 9:479–483. <https://doi.org/10.1002/mdc3.13451>
26. Thomann AE, Goettel N, Monsch RJ, Berres M, Jahn T, Steiner LA, Monsch AU (2018) The Montreal Cognitive Assessment: normative data from a German-speaking cohort and comparison with international normative samples. *J Alzheimers Dis* 64:643–655. <https://doi.org/10.3233/JAD-180080>
27. Pirogovsky E, Schiehser DM, Litvan I, Obtera KM, Burke MM, Lessig SL, Song DD, Liu L, Filoteo JV (2014) The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment. *Parkinsonism Relat Disord* 20:627–631. <https://doi.org/10.1016/j.parkreldis.2014.03.010>
28. Liepelt-Scarfone I, Gräber S, Kalbe E, Riedel O, Ringendahl H, Schmidt N, Witt K, Roeske S (2021) Empfehlungen zur neuropsychologischen Diagnostik beim Morbus Parkinson. *Fortschr Neurol Psychiatr* 89:363–373. <https://doi.org/10.1055/a-1099-9332>
29. Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, Wittchen HU, Dodel R, Otto J, Ebersbach G, Kessler J (2008) Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. *Parkinsonism Relat Disord* 14:93–101. <https://doi.org/10.1016/j.parkreldis.2007.06.008>
30. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. *Neurology* 73:1738–1745. <https://doi.org/10.1212/WNL.0b013e318c34b47>
31. Memory Clinic, Universitaere Altersmedizin FELIX PLATTER, Basel (2024) Die Neuropsychologische Testbatterie CERAD-Plus. <https://www.memoryclinic.ch/de/main-navigation/neuropsychologen/cerad-plus>. Accessed 9 Apr 2024
32. Barton BR, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG (2014) Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. *Mov Disord* 29:1252–1257. <https://doi.org/10.1002/mds.25902>
33. Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT (2015) Diagnosing PD-MCI by MDS task force criteria: How many and which neuropsychological tests? *Mov Disord* 30:402–406. <https://doi.org/10.1002/mds.26084>
34. Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D, IPMDS Study Group "Validation of Mild Cognitive Impairment in Parkinson Disease" (2018) Detecting mild cognitive deficits in Parkinson's disease: comparison of neuropsychological tests. *Mov Disord* 33:1750–1759. <https://doi.org/10.1002/mds.110>
35. Bezdicek O, Stepankova H, Martinec Novakova L, Kopecek M (2016) Toward the processing speed theory of activities of daily living in healthy aging: normative data of the Functional Activities Questionnaire. *Aging Clin Exp Res* 28:239–247. <https://doi.org/10.1007/s40520-015-0413-5>
36. Sikkes SA, de Lange-de Klerk ES, Pijnenburg YA, Scheltens P, Uitdehaag BM (2009) A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement. *J Neurol Neurosurg Psychiatry* 80:7–12. <https://doi.org/10.1136/jnnp.2008.155838>
37. Dujardin K, Dubois B, Tison F, Durif F, Bourdeix I, Péré JJ, Duhamel A, EXECUTIVE study group (2010) Parkinson's disease dementia can be easily detected in routine clinical practice. *Mov Disord* 25:2769–2776. <https://doi.org/10.1002/mds.23391>
38. Giovannetti T, Britnell P, Brennan L, Siderowf A, Grossman M, Libon DJ, Betcher BM, Rouzard F, Eppig J, Seidel GA (2012) Everyday action impairment in Parkinson's disease dementia. *J Int Neuropsychol Soc* 18:787–798. <https://doi.org/10.1017/S135561771200046X>
39. Leroi I, McDonald K, Pantula H, Harbisetar V (2012) Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. *J Geriatr Psychiatry Neurol* 25:208–214. <https://doi.org/10.1177/0891988712464823>
40. Stella F, Banzato CEM, Quagliato EMAB, Viana MA, Cristofolletti G (2008) Dementia and functional decline in patients with Parkinson's disease. *Dement Neuropsychol* 2:96–101. <https://doi.org/10.1590/S1980-57642009DN20200004>
41. Wahle M, Hüller S, Spiegel R (1996) Validation of the NOS-GER (Nurses' Observation Scale for Geriatric Patients): reliability and validity of a caregiver rating instrument. *Int Psychogeriatr* 8:525–547. <https://doi.org/10.1017/s1041610296002864>
42. Christ JB, Berger MF, Riedel E, Prakash D, Csoti I, Molt W, Gräber S, Brockmann K, Berg D, Liepelt-Scarfone I (2013) How precise are activities of daily living scales for the diagnosis of Parkinson's disease dementia? A pilot study. *Parkinsonism Relat Disord* 19:371–374. <https://doi.org/10.1016/j.parkreldis.2012.11.004>
43. Kulisevsky J, Fernández de Bobadilla R, Pagonabarraga J, Martínez-Horta S, Campolongo A, García-Sánchez C, Pascual-Sedano B, Ribosa-Nogué R, Villa-Bonomo C (2013) Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. *Parkinsonism Relat Disord* 19:812–817. <https://doi.org/10.1016/j.parkreldis.2013.05.007>
44. Martinez-Martin P (2013) Dementia in Parkinson's disease: usefulness of the pill questionnaire. *Mov Disord* 28:1832–1837. <https://doi.org/10.1002/mds.25649>
45. Bahar-Fuchs A, Martyr A, Goh AM, Sabates J, Clare L (2019) Cognitive training for people with mild to moderate dementia. *Cochrane Database Syst Rev* 3:CD013069. <https://doi.org/10.1002/14651858.CD013069.pub2>
46. Alloni A, Quaglini S, Panzarasa S, Sinforiani E, Bernini S (2018) Evaluation of an ontology-based system for computerized cognitive rehabilitation. *Int J Med Inform* 115:64–72. <https://doi.org/10.1016/j.ijmedinf.2018.04.005>
47. Bernini S, Panzarasa S, Barbieri M, Sinforiani E, Quaglini S, Tassorelli C, Bottiroli S (2021) A double-blind randomized controlled trial of the efficacy of cognitive training delivered using two different methods in mild cognitive impairment in Parkinson's disease: preliminary report of benefits associated with the

- use of a computerized tool. *Aging Clin Exp Res* 33:1567–1575. <https://doi.org/10.1007/s40520-020-01665-2>
48. De Luca R, Latella D, Maggio MG, Di Lorenzo G, Maresca G, Sciarrone F, Militi D, Bramanti P, Calabrò RS (2019) Computer assisted cognitive rehabilitation improves visuospatial and executive functions in Parkinson's disease: preliminary results. *NeuroRehabilitation* 45:285–290. <https://doi.org/10.3233/NRE-192789>
 49. Paris AP, Saleta HG, de la Cruz Crespo Maraver M, Silvestre E, Freixa MG, Torrellas CP, Pont SA, Nadal MF, Garcia SA, Bartolomé MV, Fernández VL, Bayés AR (2011) Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. *Mov Disord* 26:1251–1258. <https://doi.org/10.1002/mds.23688>
 50. Lawrence BJ, Gasson N, Johnson AR, Booth L, Loftus AM (2018) Cognitive training and transcranial direct current stimulation for mild cognitive impairment in Parkinson's disease: a randomized controlled trial. *Parkinsons Dis* 2018:4318475. <https://doi.org/10.1155/2018/4318475>
 51. Vlagsma TT, Duits AA, Dijkstra HT, van Laar T, Spikman JM (2020) Effectiveness of ReSET; a strategic executive treatment for executive dysfunctioning in patients with Parkinson's disease. *Neuropsychol Rehabil* 30:67–84. <https://doi.org/10.1080/09602011.2018.1452761>
 52. Maggio MG, De Cola MC, Latella D, Maresca G, Finocchiaro C, La Rosa G, Cimino V, Sorbera C, Bramanti P, De Luca R, Calabrò RS (2018) What about the role of virtual reality in Parkinson disease's cognitive rehabilitation? Preliminary findings from a randomized clinical trial. *J Geriatr Psychiatry Neurol* 31:312–318. <https://doi.org/10.1177/0891988718807973>
 53. van de Weijer SCF, Duits AA, Bloem BR, de Vries NM, Kessels RPC, Köhler S, Tissingh G, Kuijff ML (2020) Feasibility of a cognitive training game in Parkinson's disease: the randomized Parkin'Play study. *Eur Neurol* 83:426–432. <https://doi.org/10.1159/000509685>
 54. Sousa NMF, Neri A, Brandi IV, Brucki SMD (2021) Impact of cognitive intervention on cognitive symptoms and quality of life in idiopathic Parkinson's disease: a randomized and controlled study. *Dement Neuropsychol* 15:51–59. <https://doi.org/10.1590/1980-57642021dn15-010005>
 55. Angelucci F, Peppe A, Carlesimo GA, Serafini F, Zabberoni S, Barban F, Shofany J, Caltagirone C, Costa A (2015) A pilot study on the effect of cognitive training on BDNF serum levels in individuals with Parkinson's disease. *Front Hum Neurosci* 9:130. <https://doi.org/10.3389/fnhum.2015.00130>
 56. Costa A, Peppe A, Serafini F, Zabberoni S, Barban F, Caltagirone C, Carlesimo GA (2014) Prospective memory performance of patients with Parkinson's disease depends on shifting aptitude: evidence from cognitive rehabilitation. *J Int Neuropsychol Soc* 20(7):717–726. <https://doi.org/10.1017/S1355617714000563>
 57. Kalbe E, Folkerts AK, Ophey A, Eggers C, Elben S, Dimen-shiteyn K, Sulzer P, Schulte C, Schmidt N, Schlenstedt C, Berg D, Witt K, Wojtecki L, Liepelt-Scarfone I (2020) Enhancement of executive functions but not memory by multidomain group cognitive training in patients with Parkinson's disease and mild cognitive impairment: a multicenter randomized controlled trial. *Parkinsons Dis* 2020:4068706. <https://doi.org/10.1155/2020/4068706>
 58. Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A (2015) Cognitive training in Parkinson disease: a systematic review and meta-analysis. *Neurology* 85:1843–1851. <https://doi.org/10.1212/WNL.0000000000002145>
 59. Gavelin HM, Domellöf ME, Leung I, Neely AS, Launder NH, Nategh L, Finke C, Lampit A (2022) Computerized cognitive training in Parkinson's disease: a systematic review and meta-analysis. *Ageing Res Rev* 80:101671. <https://doi.org/10.1016/j.arr.2022.101671>
 60. Lawrence BJ, Gasson N, Bucks RS, Troeung L, Loftus AM (2017) Cognitive training and noninvasive brain stimulation for cognition in Parkinson's disease: a meta-analysis. *Neurorehabil Neural Repair* 31:597–606. <https://doi.org/10.1177/1545968317712468>
 61. Woods B, Kaur Rai H, Elliott E, Aguirre E, Orrel M, Spector A (2023) Cognitive stimulation to improve cognitive functioning in people with dementia. *Cochrane Database Syst Rev* 1:CD005562. <https://doi.org/10.1002/14651858.CD005562.pub3>
 62. Folkerts AK, Dorn ME, Roheger M, Maassen M, Koerts J, Tucha O, Altgassen M, Sack AT, Smit D, Haarmann L, Kalbe E (2018) Cognitive stimulation for individuals with Parkinson's disease dementia living in long-term care: preliminary data from a randomized crossover pilot study. *Parkinsons Dis* 2018:8104673. <https://doi.org/10.1155/2018/8104673>
 63. Woods B, O'Philbin L, Farrell EM, Spector AE, Orrell M (2018) Reminiscence therapy for dementia. *Cochrane Database Syst Rev* 3:CD001120. <https://doi.org/10.1002/14651858.CD001120.pub3>
 64. Sofi F, Valecchi D, Bacci D, Abbate R, Gensini GF, Casini A, Macchi C (2011) Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. *J Intern Med* 269:107–117. <https://doi.org/10.1111/j.1365-2796.2010.02281.x>
 65. Hamer M, Chida Y (2009) Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychol Med* 39:3–11. <https://doi.org/10.1017/S0033291708003681>
 66. Zeng Y, Wang J, Cai X, Zhang X, Zhang J, Peng M, Xiao D, Ouyang H, Yan F (2023) Effects of physical activity interventions on executive function in older adults with dementia: a meta-analysis of randomized controlled trials. *Geriatr Nurs* 51:369–377. <https://doi.org/10.1016/j.gerinurse.2023.04.012>
 67. Folkerts AK, Ernst M, Gollan R, Cryns N, Monsef I, Skoetz N, Kalbe E (2024) Can physical exercise be considered as a promising enhancer of global cognition in people with Parkinson's disease? Results of a systematic review and meta-analysis. *J Parkinsons Dis*. <https://doi.org/10.3233/JPD-230343>
 68. Paul KC, Chuang YH, Shih IF, Keener A, Bordonon Y, Bronstein JM, Ritz B (2019) The association between lifestyle factors and Parkinson's disease progression and mortality. *Mov Disord* 34:58–66. <https://doi.org/10.1002/mds.27577>
 69. Avenali M, Picascia M, Tassorelli C, Sinforiani E, Bernini S (2021) Evaluation of the efficacy of physical therapy on cognitive decline at 6-month follow-up in Parkinson disease patients with mild cognitive impairment: a randomized controlled trial. *Aging Clin Exp Res* 33:3275–3284. <https://doi.org/10.1007/s40520-021-01865-4>
 70. Silveira CRA, Roy EA, Intzandt BN, Almeida QJ (2018) Aerobic exercise is more effective than goal-based exercise for the treatment of cognition in Parkinson's disease. *Brain Cogn* 122:1–8. <https://doi.org/10.1016/j.bandc.2018.01.002>
 71. Picelli A, Varalta V, Melotti C, Zatezalo V, Fonte C, Amato S, Saltuari L, Santamato A, Fiore P, Smania N (2016) Effects of treadmill training on cognitive and motor features of patients with mild to moderate Parkinson's disease: a pilot, single-blind, randomized controlled trial. *Funct Neurol* 31:25–31. <https://doi.org/10.11138/fneur/2016.31.1.025>
 72. Altmann LJ, Stegemöller E, Hazamy AA, Wilson JP, Bowers D, Okun MS, Hass CJ (2016) Aerobic exercise improves mood, cognition, and language function in Parkinson's disease: results of a controlled study. *J Int Neuropsychol Soc* 22:878–889. <https://doi.org/10.1017/S135561771600076X>
 73. da Silva FC, Iop RDR, de Oliveira LC, Boll AM, de Alvarenga JGS, Gutierrez Filho PJB, Bezerra A, de Melo LM (2018) Effects of physical exercise programs on cognitive

- function in Parkinson's disease patients: a systematic review of randomized controlled trials of the last 10 years. *PLoS ONE* 13:e01931. <https://doi.org/10.1371/journal.pone.0193113>
74. Inskip MJ, Mavros Y, Sachdev PS, Hausdorff JM, Hillel I, Singh MAF (2022) Promoting independence in Lewy body dementia through exercise: the PRIDE study. *BMC Geriatr* 22(1):650. <https://doi.org/10.1186/s12877-022-03347-2>
 75. Tabak R, Aquije G, Fisher BE (2013) Aerobic exercise to improve executive function in Parkinson disease: a case series. *J Neurol Phys Ther* 37(2):58–64. <https://doi.org/10.1097/NPT.0b013e31829219bc>
 76. Telenius EW, Engedal K, Bergland A (2015) Effect of a high-intensity exercise program on physical function and mental health in nursing home residents with dementia: an assessor blinded randomized controlled trial. *PLoS ONE* 10:e01261. <https://doi.org/10.1371/journal.pone.0126102>
 77. Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP (2018) Low-fat versus ketogenic diet in Parkinson's disease: a pilot randomized controlled trial. *Mov Disord* 33:1306–1314. <https://doi.org/10.1002/mds.27390>
 78. Paknahad Z, Sheklabadi E, Derakhshan Y, Bagherniya M, Chit-saz A (2020) The effect of the Mediterranean diet on cognitive function in patients with Parkinson's disease: a randomized clinical controlled trial. *Complement Ther Med* 50:102366. <https://doi.org/10.1016/j.ctim.2020.102366>
 79. Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, Zhang J, Sun C, Zhang Y, Ju X (2015) The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson's disease. *Eur Neurol* 73:205–211. <https://doi.org/10.1159/000377676>
 80. Cho BH, Choi SM, Kim JT, Kim BC (2018) Association of coffee consumption and non-motor symptoms in drug-naïve, early-stage Parkinson's disease. *Parkinsonism Relat Disord* 50:2–47. <https://doi.org/10.1016/j.parkreldis.2018.02.016>
 81. Cho BH, Choi SM, Kim BC (2019) Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson's disease. *BMC Neurol* 19:194. <https://doi.org/10.1186/s12883-019-1427-y>
 82. Zhang C, Zang Y, Song Q, Li H, Hu L, Zhao W, Feng S, Gu F, Zhao F, Zhang C (2019) The efficacy of a “cocktail therapy” on Parkinson's disease with dementia. *Neuropsychiatr Dis Treat* 15:1639–1647. <https://doi.org/10.2147/NDT.S179453>
 83. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD (2005) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. *Neurology* 65:1716–1722. <https://doi.org/10.1212/01.wnl.0000191154.78131.f6>
 84. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thal LJ, Corey-Bloom J (2000) Cholinergic dysfunction in diseases with Lewy bodies. *Neurology* 54:407–411. <https://doi.org/10.1212/wnl.54.2.407>
 85. van der Zee S, Müller ML, Kanel P, van Laar T, Bohnen NI (2021) Cholinergic denervation patterns across cognitive domains in Parkinson's disease. *Mov Disord* 36:642–650. <https://doi.org/10.1002/mds.28360>
 86. Gargouri F, Gallea C, Mongin M, Pyatigorskaya N, Valabregue R, Evenczyk C, Sarazin M, Yahia-Cherif L, Vidailhet M, Lehéricy S (2019) Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease. *Mov Disord* 34:516–525. <https://doi.org/10.1002/mds.27561>
 87. van der Zee S, Kanel P, Gerritsen MJJ, Boertien JM, Slomp AC, Müller MLTM, Bohnen NI, Spikman JM, van Laar T (2022) Altered cholinergic innervation in de novo Parkinson's disease with and without cognitive impairment. *Mov Disord* 37:713–723. <https://doi.org/10.1002/mds.28913>
 88. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J (2019) Memantine for dementia. *Cochrane Database Syst Rev* 3:CD003154. <https://doi.org/10.1002/14651858.CD003154.pub>
 89. Tsujihashi H, Matsuda H, Uejima S, Akiyama T, Kurita T (1989) Role of natural killer cells in bladder tumor. *Eur Urol* 16:444–449. <https://doi.org/10.1159/000471637>
 90. Baik K, Kim SM, Jung JH, Lee YH, Chung SJ, Yoo HS, Ye BS (2021) Donepezil for mild cognitive impairment in Parkinson's disease. *Sci Rep* 11(1):4734. <https://doi.org/10.1038/s41598-021-84243-4>
 91. Sawada H, Oeda T, Kohsaka M, Umemura A, Tomita S, Park K, Mizoguchi K, Matsuo H, Hasegawa K, Fujimura H, Sugiyama H, Nakamura M, Kikuchi S, Yamamoto K, Fukuda T, Ito S, Goto M, Kiyohara K, Kawamura T (2018) Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years. *J Neurol Neurosurg Psychiatry* 89:1332–1340. <https://doi.org/10.1136/jnnp-2018-318107>
 92. Sawada H, Oeda T, Kohsaka M, Tomita S, Umemura A, Park K, Yamamoto K, Kiyohara K (2021) Early-start vs. delayed-start donepezil against cognitive decline in Parkinson disease: a randomized clinical trial. *Expert Opin Pharmacother* 22:363–371. <https://doi.org/10.1080/14656566.2020.1814255>
 93. Kawashima S, RCIP-Nagoya Study Group, Matsukawa N (2022) Memantine for the patients with mild cognitive impairment in Parkinson's disease: a pharmacological fMRI study. *BMC Neurol* 22:175. <https://doi.org/10.1186/s12883-022-02699-x>
 94. Rolinski M, Fox C, Maidment I, McShane R (2012) Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. *Cochrane Database Syst Rev* 2012:CD006504. <https://doi.org/10.1002/14651858.CD006504.pub2>
 95. Pagano G, Rengo G, Pasqualetti G, Femminella GD, Monzani F, Ferrara N, Tagliati M (2015) Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry* 86:767–773. <https://doi.org/10.1136/jnnp-2014-308764>
 96. Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, Wang C, Tan MS, Tan L (2015) Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. *J Neurol Neurosurg Psychiatry* 86:135–143. <https://doi.org/10.1136/jnnp-2014-307659>
 97. Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O'Brien JT (2015) Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. *Am J Psychiatry* 172:731–742. <https://doi.org/10.1176/appi.ajp.2015.14121582>
 98. Matsunaga S, Kishi T, Yasue I, Iwata N (2016) Cholinesterase inhibitors for Lewy body disorders: a meta-analysis. *Int J Neuropsychopharmacol* 19:pyv086. <https://doi.org/10.1093/ijnpyv086>
 99. Brennan L, Pantelyat A, Duda JE, Morley JF, Weintraub D, Wilkinson JR, Moberg PJ (2016) Memantine and cognition in Parkinson's disease dementia/dementia with Lewy bodies: a meta-analysis. *Mov Disord Clin Pract* 3:161–167. <https://doi.org/10.1002/mdc3.12264>
 100. Broen MP, Narayan NE, Kuijff ML, Dissanayaka NN, Leentjens AF (2016) Prevalence of anxiety in Parkinson's disease: a systematic review and meta-analysis. *Mov Disord* 31:1125–1133. <https://doi.org/10.1002/mds.26643>
 101. den Brok MG, van Dalen JW, van Gool WA, Moll van Charante EP, de Bie RM, Richard E (2015) Apathy in Parkinson's disease: a systematic review and meta-analysis. *Mov Disord* 30:759–769. <https://doi.org/10.1002/mds.26208>

102. Schrag A (2006) Quality of life and depression in Parkinson's disease. *J Neurol Sci* 248:151–157. <https://doi.org/10.1016/j.jns.2006.05.030>
103. Burn DJ (2002) Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson's disease. *Mov Disord* 17:445–454. <https://doi.org/10.1002/mds.10114>
104. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ (2002) Non-recognition of depression and other non-motor symptoms in Parkinson's disease. *Parkinsonism Relat Disord* 8:193–197. [https://doi.org/10.1016/s1353-8020\(01\)00015-3](https://doi.org/10.1016/s1353-8020(01)00015-3)
105. Richard IH, Kurlan R (1997) A survey of antidepressant drug use in Parkinson's disease. *Parkinson Study Group. Neurology* 49:1168–1170. <https://doi.org/10.1212/wnl.49.4.1168>
106. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB (2003) Recognition and treatment of depression in Parkinson's disease. *J Geriatr Psychiatry Neurol* 16:178–183. <https://doi.org/10.1177/0891988703256053>
107. Bundesinstitut für Arzneimittel und Medizinprodukte (2022) ICD-11 in Deutsch-Entwurfsvfassung. https://www.bfarm.de/DE/Kodiersysteme/Klassifikationen/ICD/ICD-11/uebersetzung/_node.html?sessionid=272C7E204316C0BDAB6ABCAC99C2E713.internet271. Accessed 13 June 2023
108. Reiff J, Schmidt N, Riebe B, Breternitz R, Aldenhoff J, Deuschl G, Witt K (2011) Subthreshold depression in Parkinson's disease. *Mov Disord* 26:1741–1744. <https://doi.org/10.1002/mds.23699>
109. Qin Z, Zhang L, Sun F, Liu H, Fang X, Chan P (2009) Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: results from Chinese L-dopa exposed cohort. *Clin Neurol Neurosurg* 111:733–737. <https://doi.org/10.1016/j.clineuro.2009.07.001>
110. Cong S, Xiang C, Zhang S, Zhang T, Wang H, Cong S (2022) Prevalence and clinical aspects of depression in Parkinson's disease: a systematic review and meta-analysis of 129 studies. *Neurosci Biobehav Rev* 141:104749. <https://doi.org/10.1016/j.neubiorev.2022.104749>
111. Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG (2008) Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. *Mov Disord* 23:2004–2014. <https://doi.org/10.1002/mds.22229>
112. Nagayama H, Maeda T, Uchiyama T, Hashimoto M, Nomoto N, Kano O, Takahashi T, Terashi H, Hamada S, Hasegawa T, Hatano T, Takahashi T, Baba Y, Sengoku R, Watanabe H, Inoue M, Kadowaki T, Kaneko S, Shimura H, Kubo SI, Young Japanese Expert Group for Parkinson's Disease and Movement Disorders: YJ-EXPANDS (2017) Anhedonia and its correlation with clinical aspects in Parkinson's disease. *J Neurol Sci* 372:403–407. <https://doi.org/10.1016/j.jns.2016.10.051>
113. van der Velden RMJ, Broen MPG, Kuijf ML, Leentjens AFG (2018) Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: a systematic review. *Mov Disord* 33:1521–1527. <https://doi.org/10.1002/mds.27465>
114. Berg P, Book K, Dinkel A, Henrich G, Marten-Mittag B, Mertens D, Ossner C, Volmer S, Herschbach P (2011) Progredienzanst bei chronischen Erkrankungen [Fear of progression in chronic diseases]. *Psychother Psychosom Med Psychol* 61:32–37. <https://doi.org/10.1055/s-0030-1267927>
115. Folkerts AK, Haarmann L, Nielsen J, Saliger J, Eschweiler M, Karbe H, Allert N, Vida V, Trenkwalder C, Kruse A, Oelsner H, Ebersbach G, Kalbe E (2022) Fear of progression is determined by anxiety and self-efficacy but not disease-specific parameters in patients with Parkinson's disease: preliminary data from a multicenter cross-sectional study. *J Parkinsons Dis* 12:2543–2553. <https://doi.org/10.3233/JPD-223314>
116. Kluger BM, Herlofson K, Chou KL, Lou JS, Goetz CG, Lang AE, Weintraub D, Friedman J (2016) Parkinson's disease-related fatigue: a case definition and recommendations for clinical research. *Mov Disord* 31:625–631. <https://doi.org/10.1002/mds.26511>
117. Lou JS (2009) Physical and mental fatigue in Parkinson's disease: epidemiology, pathophysiology and treatment. *Drugs Aging* 26:195–208. <https://doi.org/10.2165/00002512-200926030-00002>
118. Metta V, Logishetty K, Martinez-Martin P, Gage HM, Schartau PE, Kaluarachchi TK, Martin A, Odin P, Barone P, Stocchi F, Antonini A, Chaudhuri KR (2011) The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project. *Parkinsons Dis* 2011:25271. <https://doi.org/10.4061/2011/125271>
119. Friedman JH, Friedman H (2001) Fatigue in Parkinson's disease: a 9-year follow-up. *Mov Disord* 16:1120–1122. <https://doi.org/10.1002/mds.1201>
120. Herlofson K, Kluger BM (2017) Fatigue in Parkinson's disease. *J Neurol Sci* 374:38–41. <https://doi.org/10.1016/j.jns.2016.12.061>
121. Schwarz J, Odin P, Buhmann C, Csoti I, Jost W, Wüllner U, Storch A (2011) Depression in Parkinson's disease. *J Neurol* 258:336–338. <https://doi.org/10.1007/s00415-011-6048-3>
122. Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD (1988) Depression and disability in Parkinson's disease: a follow-up of 132 cases. *Psychol Med* 18:49–55. <https://doi.org/10.1017/s0033291700001872>
123. Storch A, Ebersbach G, Fuchs G, Jost WH, Odin P, Reifschneider G, Bauer M (2008) Depression beim idiopathischen Parkinson-syndrom. Teil 1: epidemiologie, pathophysiologie, klinik und diagnostik [Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis]. *Fortschr Neurol Psychiatr* 76:715–724. <https://doi.org/10.1055/s-2008-1038293>
124. Kummer A, Cardoso F, Teixeira AL (2009) Suicidal ideation in Parkinson's disease. *CNS Spectr* 14:431–436. <https://doi.org/10.1017/s109285290002040x>
125. Lemke MR (2008) Depressive symptoms in Parkinson's disease. *Eur J Neurol* 15:21–25. <https://doi.org/10.1111/j.1468-1331.2008.02058.x>
126. Pagonabarraga J, Kulisevsky J (2017) Apathy in Parkinson's disease. *Int Rev Neurobiol* 133:657–678. <https://doi.org/10.1016/bs.irn.2017.05.025>
127. Kluger BM (2017) Fatigue in Parkinson's disease. *Int Rev Neurobiol* 133:743–768. <https://doi.org/10.1016/bs.irn.2017.05.007>
128. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG (2007) Depression rating scales in Parkinson's disease: critique and recommendations. *Mov Disord* 22:1077–1092. <https://doi.org/10.1002/mds.21333>
129. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD (1987) Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. *Psychol Med* 17:899–904. <https://doi.org/10.1017/s0033291700000702>
130. Raudino F (2001) Non motor off in Parkinson's disease. *Acta Neurol Scand* 104:312–315. <https://doi.org/10.1034/j.1600-0404.2001.00357.x>
131. Zhang Q, Yang X, Song H, Jin Y (2020) Cognitive behavioral therapy for depression and anxiety of Parkinson's disease: a systematic review and meta-analysis. *Complement Ther Clin Pract* 39:101111. <https://doi.org/10.1016/j.ctcp.2020.101111>
132. Luo F, Ye M, Lv T, Hu B, Chen J, Yan J, Wang A, Chen F, He Z, Ding Z, Zhang J, Qian C, Liu Z (2021) Efficacy of cognitive behavioral therapy on mood disorders, sleep, fatigue, and quality of life in Parkinson's disease: a systematic review and

- meta-analysis. *Front Psychiatry* 12:793804. <https://doi.org/10.3389/fpsy.2021.793804>
133. Xie CL, Wang XD, Chen J, Lin HZ, Chen YH, Pan JL, Wang WW (2015) A systematic review and meta-analysis of cognitive behavioral and psychodynamic therapy for depression in Parkinson's disease patients. *Neurol Sci* 36:833–843. <https://doi.org/10.1007/s10072-015-2118-0>
 134. Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S (2015) Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis. *Parkinsonism Relat Disord* 21:833–842. <https://doi.org/10.1016/j.parkreldis.2015.04.018>
 135. Tian J, Kang Y, Liu P, Yu H (2022) Effect of physical activity on depression in patients with Parkinson's disease: a systematic review and meta-analysis. *Int J Environ Res Public Health* 19:6849. <https://doi.org/10.3390/ijerph19116849>
 136. Yang Y, Wang G, Zhang S, Wang H, Zhou W, Ren F, Liang H, Wu D, Ji X, Hashimoto M, Wei J (2022) Efficacy and evaluation of therapeutic exercises on adults with Parkinson's disease: a systematic review and network meta-analysis. *BMC Geriatr* 22:813. <https://doi.org/10.1186/s12877-022-03510-9>
 137. Gollan R, Ernst M, Lieker E, Caro-Valenzuela J, Monsef I, Dresen A, Roheger M, Skoetz N, Kalbe E, Folkerts AK (2022) Effects of resistance training on motor- and non-motor symptoms in patients with Parkinson's disease: a systematic review and meta-analysis. *J Parkinsons Dis* 12:1783–1806. <https://doi.org/10.3233/JPD-223252>
 138. Wang LL, Sun CJ, Wang Y, Zhan TT, Yuan J, Niu CY, Yang J, Huang S, Cheng L (2022) Effects of dance therapy on non-motor symptoms in patients with Parkinson's disease: a systematic review and meta-analysis. *Aging Clin Exp Res* 34:1201–1208. <https://doi.org/10.1007/s40520-021-02030-7>
 139. Zhang Q, Hu J, Wei L, Jia Y, Jin Y (2019) Effects of dance therapy on cognitive and mood symptoms in people with Parkinson's disease: a systematic review and meta-analysis. *Complement Ther Clin Pract* 36:12–17. <https://doi.org/10.1016/j.ctcp.2019.04.005>
 140. Wang K, Li K, Zhang P, Ge S, Wen X, Wu Z, Yao X, Jiao B, Sun P, Lv P, Lu L (2021) Mind-body exercises for non-motor symptoms of patients with Parkinson's disease: a systematic review and meta-analysis. *Front Aging Neurosci* 13:770920. <https://doi.org/10.3389/fnagi.2021.770920>
 141. Song R, Grabowska W, Park M, Osypiuk K, Vergara-Diaz GP, Bonato P, Hausdorff JM, Fox M, Sudarsky LR, Macklin E, Wayne PM (2017) The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson's disease: a systematic review and meta-analysis. *Parkinsonism Relat Disord* 41:3–13. <https://doi.org/10.1016/j.parkreldis.2017.05.019>
 142. Jin X, Wang L, Liu S, Zhu L, Loprinzi PD, Fan X (2019) The impact of mind-body exercises on motor function, depressive symptoms, and quality of life in Parkinson's disease: a systematic review and meta-analysis. *Int J Environ Res Public Health* 17:31. <https://doi.org/10.3390/ijerph17010031>
 143. Cugusi L, Solla P, Serpe R, Carzedda T, Piras L, Oggianu M, Gabba S, Di Blasio A, Bergamin M, Cannas A, Marrosu F, Mercurio G (2015) Effects of a Nordic Walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease. *NeuroRehabilitation* 37:245–254. <https://doi.org/10.3233/NRE-151257>
 144. Sacheli MA, Neva JL, Lakhani B, Murray DK, Vafai N, Shahinfard E, English C, McCormick S, Dinelle K, Neilson N, McKenzie J, Schulzer M, McKenzie DC, Appel-Cresswell S, McKeown MJ, Boyd LA, Sossi V, Stoessl AJ (2019) Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. *Mov Disord* 34:1891–1900. <https://doi.org/10.1002/mds.27865>
 145. Sajatovic M, Ridgel AL, Walter EM, Tatsuoka CM, Colón-Zimmermann K, Ramsey RK, Welter E, Gunzler SA, Whitney CM, Walter BL (2017) A randomized trial of individual versus group-format exercise and self-management in individuals with Parkinson's disease and comorbid depression. *Patient Prefer Adherence* 11:965–973. <https://doi.org/10.2147/PPA.S135551>
 146. Abuofar R, AlKaabi R, Mohamed Saleh A, Zerough U, Hartley T, van Niekerk SM, Khalil H, Morris LD (2023) The effect of physical exercise on anxiety in people with Parkinson's disease: a systematic review of randomized control trials. *NeuroRehabilitation* 52:387–402. <https://doi.org/10.3233/NRE-220264>
 147. Herschbach P, Book K, Dinkel A, Berg P, Waadt S, Duran G, Engst-Hastreiter U, Henrich G (2010) Evaluation of two group therapies to reduce fear of progression in cancer patients. *Support Care Cancer* 18:471–479. <https://doi.org/10.1007/s00520-009-0696-1>
 148. Jiang C, Luo Y, Qu Y, Wang C, Li Z, Zhou J, Xu Z (2023) Pharmacological and behavioral interventions for fatigue in Parkinson's disease: a meta-analysis of randomized controlled trials. *J Geriatr Psychiatry Neurol* 36:487–495. <https://doi.org/10.1177/08919887231163291>
 149. Bogosian A, Hurt CS, Hindle JV, McCracken LM, Vasconcelos e Sa DA, Axell S, Tapper K, Stevens J, Hirani PS, Salhab M, Ye W, Cubi-Molla P (2022) Acceptability and feasibility of a mindfulness intervention delivered via videoconferencing for people with Parkinson's. *J Geriatr Psychiatry Neurol* 35:155–167. <https://doi.org/10.1177/0891988720988901>
 150. Elbers RG, Verhoeve J, van Wegen EE, Berendse HW, Kwakkel G (2015) Interventions for fatigue in Parkinson's disease. *Cochrane Database Syst Rev* 2015:CD010925. <https://doi.org/10.1002/14651858.CD010925.pub2>
 151. Folkerts AK, Nielsen J, Gollan R, Lansu A, Solfronk D, Monsef I, Ernst M, Nz S, Zeuner KE, Kalbe E (2023) Physical exercise as a potential treatment for fatigue in Parkinson's disease? A systematic review and meta-analysis of pharmacological and non-pharmacological interventions. *J Parkinsons Dis* 13:659–679. <https://doi.org/10.3233/JPD-225116>
 152. Witt K, Daniels C, Herzog J, Lorenz D, Volkmann J, Reiff J, Mehdorn M, Deuschl G, Krack P (2006) Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 18:397–401. <https://doi.org/10.1176/jnp.2006.18.3.397>
 153. Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 9:573–580. [https://doi.org/10.1016/S1474-4422\(10\)70106-X](https://doi.org/10.1016/S1474-4422(10)70106-X)
 154. Ji N, Meng P, Xu B, Zhou X (2022) Efficacy and safety of pramipexole in Parkinson's disease with anxiety or depression: a meta-analysis of randomised clinical trials. *Am J Transl Res* 14:1757–1764. <https://doi.org/10.1111/ene.13303>
 155. Jiang DQ, Jiang LL, Wang Y, Li MX (2021) The role of pramipexole in the treatment of patients with depression and Parkinson's disease: a meta-analysis of randomised controlled trials. *Asian J Psychiatr* 61:102691. <https://doi.org/10.1016/j.ajp.2021.102691>
 156. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ (2009) The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. *Clin Ther* 31:89–98. <https://doi.org/10.1016/j.clinthera.2009.01.012>
 157. Ziaei E, Emami Ardestani P, Chitsaz A (2022) Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: a randomised parallel-group trial. *J Res Med Sci* 27:55. https://doi.org/10.4103/jrms.jrms_790_21

158. Chung SJ, Asgharnejad M, Bauer L, Ramirez F, Jeon B (2016) Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease. *Expert Opin Pharmacother* 17:1453–1461. <https://doi.org/10.1080/14656566.2016.1202917>
159. Yan J, Ma H, Liu A, Huang J, Wu J, Yang J (2021) Efficacy and safety of rotigotine transdermal patch on neuropsychiatric symptoms of Parkinson's disease: an updated meta-analysis and systematic review. *Front Neurol* 12:722892. <https://doi.org/10.3389/fneur.2021.722892>
160. Wang HT, Wang L, He Y, Yu G (2018) Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: a meta-analysis of randomised placebo-controlled trials. *J Neurol Sci* 393:31–38. <https://doi.org/10.1016/j.jns.2018.08.003>
161. Ardouin C, Chéreau I, Llorca PM, Lhommée E, Durif F, Pollak P, Krack P (2009) Assessment of hyper- and hypodopaminergic behaviours in Parkinson's disease. *Rev Neurol* 165:845–856. <https://doi.org/10.1016/j.neurol.2009.06.003>
162. Ray Chaudhuri K, Martinez-Martin P, Antonini A, Brown RG, Friedman JH, Onofri M, Surmann E, Ghys L, Trenkwalder C (2013) Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. *Parkinsonism Relat Disord* 19:660–665. <https://doi.org/10.1016/j.parkreldis.2013.02.018>
163. Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. *J Neurol Sci* 248:266–270. <https://doi.org/10.1016/j.jns.2006.05.024>
164. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H (2005) Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. *J Neuropsychiatry Clin Neurosci* 17:214–220. <https://doi.org/10.1176/jnp.17.2.214>
165. Fabbri M, Barbosa R, Rascol O (2023) Off-time treatment options for Parkinson's disease. *Neurol Ther* 12:391–424. <https://doi.org/10.1007/s40120-022-00435-8>
166. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B (2002) Motivation, reward, and Parkinson's disease: influence of dopatherapy. *Neuropsychologia* 40:2257–2267. [https://doi.org/10.1016/s0028-3932\(02\)00108-2](https://doi.org/10.1016/s0028-3932(02)00108-2)
167. Pérez-Pérez J, Pagonabarraga J, Martínez-Horta S, Fernández-Bobadilla R, Sierra S, Pascual-Sedano B, Gironell A, Kulisevsky J (2015) Head-to-head comparison of the neuropsychiatric effect of dopamine agonists in Parkinson's disease: a prospective, cross-sectional study in non-demented patients. *Drugs Aging* 32:401–407. <https://doi.org/10.1007/s40266-015-0264-y>
168. Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A, Kistner A, Castrioto A, Xie J, Fraix V, Pelissier P, Chabardes S, Mertens P, Quesada JL, Bosson JL, Pollak P, Broussolle E, Krack P (2013) Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with pramipexole. *Brain* 136:1568–1577. <https://doi.org/10.1093/brain/awt067>
169. Castrioto A, Thobois S, Anheim M, Quesada JL, Lhommée E, Klinger H, Bichon A, Schmitt E, Durif F, Azulay JP, Houeto JL, Longato N, Philipps C, Pelissier P, Broussolle E, Moro E, Tranchant C, Fraix V, Krack P (2020) A randomised controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD. *NPJ Parkinsons Dis* 6:41. <https://doi.org/10.1038/s41531-020-00142-x>
170. Sawada H, Umemura A, Kohsaka M, Tomita S, Park K, Oeda T, Yamamoto K (2018) Pharmacological interventions for anxiety in Parkinson's disease sufferers. *Expert Opin Pharmacother* 19:1071–1076. <https://doi.org/10.1080/14656566.2018.1485650>
171. Prediger RD, Matheus FC, Schwarzbald ML, Lima MM, Vital MA (2012) Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. *Neuropharmacology* 62:115–124. <https://doi.org/10.1016/j.neuropharm.2011.08.039>
172. Troeung L, Egan SJ, Gasson N (2013) A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. *PLoS ONE* 8:e79510. <https://doi.org/10.1371/journal.pone.0079510>
173. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S (2008) Fatigue in levodopa-naïve subjects with Parkinson's disease. *Neurology* 71:481–485. <https://doi.org/10.1212/01.wnl.0000324862.29733.69>
174. Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J (2003) Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study. *Mov Disord* 18:1108–1114. <https://doi.org/10.1002/mds.10505>
175. Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L (2016) Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. *BMC Neurol* 16:90. <https://doi.org/10.1186/s12883-016-0610-7>
176. Shannon KM, Bennett JP Jr, Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. *Neurology* 49:724–728. <https://doi.org/10.1212/wnl.49.3.724>
177. Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W (2010) Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. *Mov Disord* 25:2542–2549. <https://doi.org/10.1002/mds.23317>
178. Maillet A, Météreau E, Tremblay L, Favre E, Klinger H, Lhommée E, Le Bars D, Castrioto A, Prange S, Sgambato V, Broussolle E, Krack P, Thobois S (2021) Serotonergic and dopaminergic lesions underlying parkinsonian neuropsychiatric signs. *Mov Disord* 36:2888–2900. <https://doi.org/10.1002/mds.28722>
179. Maillet A, Krack P, Lhommée E, Météreau E, Klinger H, Favre E, Le Bars D, Schmitt E, Bichon A, Pelissier P, Fraix V, Castrioto A, Sgambato-Faure V, Broussolle E, Tremblay L, Thobois S (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease. *Brain* 139:2486–2502. <https://doi.org/10.1093/brain/aww162>
180. Pagonabarraga J, Tinazzi M, Caccia C, Jost WH (2021) The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: clinical cases and a review of the literature. *J Clin Neurosci* 90:178–183. <https://doi.org/10.1016/j.jocn.2021.05.056>
181. Deutsche Gesellschaft für Neurologie e.V. (DGN) (2016) S3-leitlinie idiopathisches Parkinson-syndrom. https://register.awmf.org/assets/guidelines/030-010k_S3_Parkinson_Syndrom_Idiopathisch_2016-06-abgelaufen.pdf. Accessed 9 Apr 2024
182. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V (2010) Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. *BMC Neurol* 10:49. <https://doi.org/10.1186/1471-2377-10-49>
183. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. *Mov Disord* 26:2–41. <https://doi.org/10.1002/mds.23829>
184. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. *Neurology*

- 72:886–892. <https://doi.org/10.1212/01.wnl.0000336340.89821.b3>
185. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE (1980) Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. *Acta Neurol Scand* 62:210–219. <https://doi.org/10.1111/j.1600-0404.1980.tb03028.x>
 186. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destée A, Bordet R, Defebvre L (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. *Mov Disord* 23:850–857. <https://doi.org/10.1002/mds.21966>
 187. Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A (2009) The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. *Mov Disord* 24:1325–1332. <https://doi.org/10.1002/mds.22586>
 188. Antonini A, Tesei S, Zecchinelli A, Barone P, De Gaspari D, Canesi M, Sacilotto G, Meucci N, Mariani C, Pezzoli G (2006) Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. *Mov Disord* 21:1119–1122. <https://doi.org/10.1002/mds.20895>
 189. Meloni M, Puligheddu M, Carta M, Cannas A, Figorilli M, Defazio G (2020) Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. *Eur J Neurol* 27:779–786. <https://doi.org/10.1111/ene.14179>
 190. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC (2008) Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. *J Affect Disord* 111:351–359. <https://doi.org/10.1016/j.jad.2008.03.008>
 191. Gillman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. *Br J Pharmacol* 151:737–748. <https://doi.org/10.1038/sj.bjp.0707253>
 192. McClure EW, Daniels RN (2021) Classics in chemical neuroscience: amitriptyline. *ACS Chem Neurosci* 12:354–362. <https://doi.org/10.1021/acscchemneuro.0c00467>
 193. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group (2012) A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. *Neurology* 78:1229–1236. <https://doi.org/10.1212/WNL.0b013e3182516244>
 194. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C (1997) Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. *Parkinson Study Group. Neurology* 10748:1070–1077. <https://doi.org/10.1212/wnl.48.4.1070>
 195. Brogden RN, Heel RC, Speight TM, Avery GS (1981) Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. *Drugs* 21:401–429. <https://doi.org/10.2165/00003495-198121060-00001>
 196. Werneck AL, Rosso AL, Vincent MB (2009) The use of an antagonist 5-HT_{2A/C} for depression and motor function in Parkinson's disease. *Arq Neuropsiquiatr* 67:407–412. <https://doi.org/10.1590/s0004-282x2009000300007>
 197. Peña E, Mata M, López-Manzanares L, Kurtis M, Eimil M, Martínez-Castrillo JC, Navas I, Posada IJ, Prieto C, Ruíz-Huete C, Vela L, Venegas B, on behalf of the movement disorder study group of the Neurological Association of Madrid (2018) Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid. *Neurologia* 33:395–402. <https://doi.org/10.1016/j.nrleng.2016.02.017>
 198. Lenze EJ, Mulsant BH, Shear MK, Dew MA, Miller MD, Pollock BG, Houck P, Tracey B, Reynolds CF III (2005) Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. *Am J Psychiatry* 162:146–150. <https://doi.org/10.1176/appi.ajp.162.1.146>
 199. Varia I, Rauscher F (2002) Treatment of generalized anxiety disorder with citalopram. *Int Clin Psychopharmacol* 17:103–107. <https://doi.org/10.1097/00004850-200205000-00002>
 200. Onofri M, Luciano AL, Thomas A, Iacono D, D'Andreamatteo G (2003) Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. *Neurology* 60:113–115. <https://doi.org/10.1212/01.wnl.0000042084.03066.c0>
 201. Anttila SA, Leinonen EV (2001) A review of the pharmacological and clinical profile of mirtazapine. *CNS Drug Rev* 7:249–264. <https://doi.org/10.1111/j.1527-3458.2001.tb00198.x>
 202. Fawcett J, Barkin RL (1998) Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. *J Affect Disord* 51:267–285. [https://doi.org/10.1016/s0165-0327\(98\)00224-9](https://doi.org/10.1016/s0165-0327(98)00224-9)
 203. Hassanein EHM, Althagafy HS, Baraka MA, Abd-Alhameed EK, Ibrahim IM (2024) Pharmacological update of mirtazapine: a narrative literature review. *Naunyn Schmiedeberg Arch Pharmacol* 397:2603–2619. <https://doi.org/10.1007/s00210-023-02818-6>
 204. Kasten M, Hagenah J, Graf J, Lorwin A, Vollstedt EJ, Peters E, Katalinic A, Raspe H, Klein C (2013) Cohort profile: a population-based cohort to study non-motor symptoms in Parkinsonism (EPI-PARK). *Int J Epidemiol* 42:128–128. <https://doi.org/10.1093/ije/dys202>
 205. De Rezende Costa FJ, Rosso ALZ, Maultasch H, Nicaretta DH, Vincent MB (2012) Depression in Parkinson's disease: diagnosis and treatment. *Arq Neuropsiquiatr* 70:617–620. <https://doi.org/10.1590/s0004-282x2012000800011>
 206. Sid-Otmame L, Huot P, Panisset M (2020) Effect of antidepressants on psychotic symptoms in Parkinson disease: a review of case reports and case series. *Clin Neuropharmacol* 43:61–65. <https://doi.org/10.1097/WNF.0000000000000384>
 207. Godschalx-Dekker JA, Siegers HP (2014) Reduction of parkinsonism and psychosis with mirtazapine: a case report. *Pharmacopsychiatry* 47:81–83. <https://doi.org/10.1055/s-0034-1367014>
 208. Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K (2013) Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. *Psychogeriatrics* 13:103–107. <https://doi.org/10.1111/j.1479-8301.2012.00432.x>
 209. Nagata T, Shinagawa S, Tagai K, Nakayama K (2013) A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease. *Psychogeriatrics* 25:1199–1201. <https://doi.org/10.1017/S1041610212002037>
 210. Normann C, Hesslinger B, Frauenknecht S, Berger M, Walden J (1997) Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. *Pharmacopsychiatry* 30:263–265. <https://doi.org/10.1055/s-2007-979504>
 211. Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C (2017) Long-term effects of safinamide on mood fluctuations in Parkinson's disease. *J Parkinsons Dis* 7:629–634. <https://doi.org/10.3233/JPD-171143>
 212. Santos García D, Labandeira Guerra C, Yáñez Baña R, Cimas Hernando MI, Cabo López I, Paz González JM, Alonso Losada MG, González Palmás MJ, Martínez Miró C (2021) Safinamide improves non-motor symptoms burden in Parkinson's disease: an open-label prospective study. *Brain Sci* 11:316. <https://doi.org/10.3390/brainsci11030316>
 213. Mendonça DA, Menezes K, Jog MS (2007) Methylphenidate improves fatigue scores in Parkinson disease: a randomized

- controlled trial. *Mov Disord* 22:2070–2076. <https://doi.org/10.1002/mds.21656>
214. Lou JS, Dimitrova DM, Park BS, Johnson SC, Eaton R, Arnold G, Nutt JG (2009) Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. *Clin Neuropharmacol* 32:305–310. <https://doi.org/10.1097/WNF.0b013e3181aa916a>
 215. Tyne HL, Taylor J, Baker GA, Steiger MJ (2010) Modafinil for Parkinson's disease fatigue. *J Neurol* 257:452–456. <https://doi.org/10.1007/s00415-009-5351-8>
 216. Pauletti C, Locuratolo N, Mannarelli D, Maffucci A, Petritis A, Menini E, Fattapposta F (2023) Fatigue in fluctuating Parkinson's disease patients: possible impact of safinamide. *J Neural Transm (Vienna)* 130:915–923. <https://doi.org/10.1007/s00702-023-02654-1>
 217. Perez-Lloret S, Peralta MC, Barrantes FJ (2016) Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. *Expert Opin Pharmacother* 17:2405–2415. <https://doi.org/10.1080/14656566.2016.1254189>
 218. López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L (2019) Anticholinergic drugs in geriatric psychopharmacology. *Front Neurosci* 13:1309. <https://doi.org/10.3389/fnins.2019.01309>
 219. Aitken D, Naismith SL, Terpening Z, Lewis SJ (2014) Dysfunctional sleep beliefs in Parkinson's disease: relationships with subjective and objective sleep. *J Clin Neurosci* 21:1359–1363. <https://doi.org/10.1016/j.jocn.2013.11.031>

Authors and Affiliations

Elke Kalbe¹  · Ann-Kristin Folkerts¹  · Karsten Witt^{2,3,4}  · Carsten Buhmann⁵  · Inga Liepelt-Scarfone^{6,7,8}  · for the German Parkinson's Guidelines Group

✉ Elke Kalbe
elke.kalbe@uk-koeln.de

Ann-Kristin Folkerts
ann-kristin.folkerts@uk-koeln.de

Karsten Witt
karsten.witt@uni-oldenburg.de

Carsten Buhmann
buhmann@uke.de

Inga Liepelt-Scarfone
inga.liepelt@uni-tuebingen.de

¹ Medical Psychology | Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

² Department of Neurology, School of Medicine and Health Science, Carl Von Ossietzky University of Oldenburg, Oldenburg, Germany

³ Research Center of Neurosensory Science, Carl Von Ossietzky University of Oldenburg, Oldenburg, Germany

⁴ Department of Neurology, Evangelical Hospital, Oldenburg, Germany

⁵ Department of Neurology, University Clinic Eppendorf, Hamburg, Germany

⁶ Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Eberhard Karls Universität Tübingen, Tübingen, Germany

⁷ German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

⁸ IB-Hochschule, Stuttgart, Germany